Exploring environmental factors and gene-environment interactions in autism spectrum disorder: a pilot study by Lopes, Ana Leonie Correia Barreto
2018 
!
UNIVERSIDADE DE LISBOA 
FACULDADE DE CIÊNCIAS 






Exploring environmental factors and gene-environment 













Dissertação orientada por: 
Dra. Astrid Moura Vicente 










“Just like moons and like suns, 
With the certainty of tides, 
Just like hopes springing high, 














































First and foremost, I would like to thank Dra. Astrid for giving me the opportunity to explore and 
gather knowledge and techniques in such an amazing area of research, which I have come to esteem and 
has changed my future perspectives. Secondly, I would like to thank my colleagues who made this process 
not only educational but fun! I would like thank João and Célia for the amazing support. For not being just 
great co-supervisors, but also friends. Thank you Célia for always keeping the child inside us alive. For 
contaminating everyone with your good humor. And for the great company on the road trips to visit parents, 
which made it feel like everything but work. Thank you João for being such a great support and passing on 
your amazing lab knowledge. And for being patient even when we were melting in the lab under our lab 
coats in the 45ºC summer heat! But also, thank you for the times we laughed so hard until we cried, from 
the ridiculous scenarios and plans we create in hour heads (we will go to Monaco one day). I would also 
like to thank my other officemates who all had something to contribute, thus demonstrating the importance 
of teamwork: Ana Rita with her amazing knowledge on epigenetics, with her genuine enthusiasm on the 
subject, which would made anyone want to listen and learn. Joana, always with a sweet disposition, and 
always willing to lend a hand (also literally because of the massages she would spontaneously give around 
the office). Alexandra, AKA the master of Microsoft Word and baile funk. Maria Luis, the maternal figure 
in the office who always checked on us and brought snacks for everyone. And Sonia who was the latest 
addition to the office, and I really wish I had gotten to spend more time around her lively and positive 
energy. Last but not least, I would like to thank my mother, my best-friend, my role model. Thank you for 
showing me what amazing things women are capable of. If I get to be half the woman you are, then I will 
consider myself very successful. Thank you for being my number one fan, and believing in me so 
wholeheartedly even when I doubted myself. Thank you for never, ever saying “that might be too hard”, 
and encouraging me to challenge and break my boundaries. You truly deserve an entire book regarding my 
appreciation for you, but actions speak louder than words so I will make sure I show it every day. I would 
also like to thank my family and friends who were so supportive and helped me stay positive through 





Autism Spectrum Disorder (ASD) is a pervasive and clinically heterogeneous neurodevelopmental 
disorder by deficits in social communication and interactions skills, and repetitive and stereotyped 
behaviours. It has becomes apparent that ASD has a strong genetics component. However, the level of 
heritability is still debated: compared to older and smaller studies, results from recent studies estimate a 
lower heritability percentage (83%), thus leaving a meaningful percentage of the risk that could be 
explained by environmental factors. Exposure to potentially harmful environmental factors can result in 
neurodevelopmental issues, due to neurotoxicity. Such environmental factors include endocrine disruptive 
chemicals like BPA, PBDEs, phthalates, PAHs, pesticides, and heavy metals, which disrupts optimal 
hormonal function, as well as pharmaceutical drugs which are able to cross physiological barriers and come 
into contact with the fetus. Moreover, the incorrect metabolization of  these xenobiotics due to defective 
enzymatic activity may be linked to an increased risk of ASD. It has been suggested that individuals 
carrying polymorphisms that hinder the activity of cytochrome p450 enzymes, responsible for phase I 
metabolism, as well as UDP-glucuronosyltransferases and glutathione S-transferase enzymes responsible 
for phase II metabolism, will be more susceptible to potentially toxic chemicals. Therefore, considering the 
role played by environmental factors, this pilot study aims to investigate and contribute to the understanding 
of gene-environment interactions in ASD. In order to do this, we explored the usage of the Early Life 
Exposure Assessment Tool (ELEAT): a questionnaire which indirectly examines child’s exposure to 
exogenous factors that could be related to ASD from 3 months before conception, during pregnancy, to the 
first year of the child’s life, by analyzing maternal exposure. We aimed to investigate the type of data  that 
could be obtained from this questionnaire, how it could be treated, and ultimately how it could be related 
to genetic information obtained from probands. The questionnaire was filled by 20 Portuguese mothers who 
had been part of a previous study. Additionally, we were able to obtain 14 biological samples from the 
children whose mothers filled out the questionnaire, who were then screened for various functional 
polymorphisms in genes known to interact with the environmental factors investigated in ELEAT. Finally, 
we related probands’ genotype to exposure reported in the ELEAT. Our results suggest that mothers were 
indeed exposed to some of the environmental factors being studied by the ELEAT in these critical periods 
of neurodevelopment. Additionally, genotyping results showed that this group of probands did carry a 
number of the polymorphisms being investigated in this pilot study, which could make them more 
susceptible to certain xenobiotics. When we merged probands’ genotype to reported exposure, we 
concluded that probands may have been exposed to the chemicals they were sensitive to during 
neurodevelopment. Most of the variants investigated in this study have not been yet related to ASD, but 
have the potential to indirectly contribute to the disorder’s onset. Our results demonstrate that meaningful 
results can be obtained from combining the ELEAT with genetic information. Seeing as the general 
population is somewhat regularly exposed to some levels of these chemicals, genetic factors play a crucial 
role in increasing susceptibility and thus leading to negative consequences such as increased ASD risk. This 
pilot study is an important step for future studies that intend to use the ELEAT to identify environmental 
risk factors for ASD. These should include a large population sample, and an equal number of controls, in 
order to obtain statistical power when calculating the multiplicative effect of given environmental exposures 
with genetic liability. In conclusion, the ELEAT could play a vital role in the understanding of gene-
environment interactions, and the development of preventive strategies for autism.   
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RESUMO ALARGADO   
Introdução: A Perturbação do Espectro do Autismo (PEA) é uma perturbação do neurodesenvolvimento 
clinicamente heterogénea caracterizada por défices na capacidade de comunicação e interação social, 
interesses repetitivos e comportamentos estereotipados. A PEA inclui indivíduos que possuem desde baixo 
até alto funcionamento e pode apresentar-se acompanhada de um vasto número de co-morbilidades, como 
a Síndrome do X Frágil, epilepsia e problemas gastrointestinais, que contribuem para a sua heterogeneidade 
fenotípica. A PEA tem uma forte componente genética, com estudos recentes a estimarem uma 
heritabilidade na ordem dos 83%. Estes valores sugerem também, que uma parte do risco seja explicada 
por causas não-genéticas, nomeadamente a presença de concentrações séricas baixas de certos fatores 
nutricionais como a vitamina D e o ácido fólico já foram relacionados com o aumento do risco de 
desenvolver a perturbação. Também a exposição a tóxicos ambientais, potencialmente prejudiciais e 
neurotóxicos, pode resultar em problemas no neurodesenvolvimento, Estes incluem: disruptores endócrinos 
como o bisfenol A (BPA), éteres de difenila polibromados (PBDEs), ftalatos, hidrocarbonetos aromáticos 
policíclicos (PAHs), pesticidas e metais pesados (nomeadamente chumbo e mercúrio), que interferem com  
o funcionamento hormonal normal, bem como medicamentos capazes de atravessar as barreiras fisiológicas 
(hematoencefálica e placentária) e interferir com o feto. Estudos recentes suportam, com diferentes níveis 
de evidência, a associação entre a exposição a xenobióticos e o risco de desenvolver PEA. Tem sido 
sugerido que indivíduos portadores de polimorfismos que alteram a atividade das enzimas do citocromo 
p450, responsáveis pelo metabolismo de fase I, bem como as enzimas UDP-glucuronosiltransferases e 
glutationa S-transferases, responsáveis pelo metabolismo de fase II, serão mais suscetíveis a substâncias 
químicas potencialmente tóxicas. Normalmente, os estudos na PEA tendem a focar-se somente em fatores 
genéticos ou em fatores não-genéticos, havendo uma necessidade urgente de desenvolver abordagens que 
integrem conjuntamente as duas componentes. 
!
Objetivo:  Considerando que alguns casos de PEA poderão resultar da combinação entre a suscetibilidade 
genética individual e a exposição a fatores ambientais durante o neurodesenvolvimento, com este estudo 
piloto pretende-se investigar e contribuir para um melhor conhecimento das interações gene-ambiente na 
etiologia da PEA. 
!
Métodos:  Foi explorada a aplicação do instrumento de investigação denominado: Estudo Longitudinal da 
Exposição Ambiental a Toxinas (ELEAT) - um questionário detalhado que examina indiretamente a 
exposição das crianças a fatores exógenos que podem estar relacionados com a PEA, desde os 3 meses 
antes da conceção, no decurso da gestação e estendendo-se ao longo do primeiro ano de vida. Nesta fase 
pretendemos investigar que tipo de dados podem ser obtidos a partir deste questionário, o modo como os 
dados podem ser tratados e, finalmente, como podem ser relacionados com a informação genética 
subsequentemente obtida de probandos. Responderam ao questionário 20 mães portuguesas com pelo 
menos um filho com PEA, recrutadas através de um estudo anterior. Na avaliação da componente genética 
do estudo, 14 amostras de DNA de crianças com PEA (cujas mães preencheram o questionário) foram 
testadas para a presença de vários polimorfismos funcionais em 14 genes: ABCB1, ACHE, AHR, CYP2D6, 
CYP2C19, CYP3A4, GSTM1, MTHFR, PLCG1, PON1, TNFRSF11B, UGT1A, UGT2B15, VDR. Este 
conjunto de genes foi selecionado pela sua relação com os fatores ambientais investigados no ELEAT, e os 
polimorfismos investigados têm potencial de influenciar a forma como os indivíduos portadores respondem 
à exposição a esses fatores. Finalmente, relacionámos o genótipo dos probandos com a exposição a 
xenobióticos reportada no referido questionário. 
!
Resultados: Os resultados obtidos do ELEAT sugerem que as mães e respetivos filhos(as) foram expostos 
a alguns dos fatores ambientais estudados, durante períodos críticos para o neurodesenvolvimento. Os 
resultados da genotipagem mostraram que o grupo de probandos é portador de variantes em vários dos 
genes investigados neste estudo, o que poderá torná-los mais suscetíveis a certos xenobióticos. Foram 
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identificados portadores de alelos de menor frequência em genes como o ABCB1, ACHE, AHR, CYP2R1, 
CYP2C19, CYP3A4, PON1, UGT2B15 e VDR. Foram também encontrados indivíduos homozigóticos para 
o alelo alternativo em polimorfismos dos genes ACHE, AHR, PON1 e UGT2B15. Estes genes são 
particularmente importantes na resposta à exposição a pesticidas, PAHs e BPA, o que poderá ter um impacto 
na forma como os seus portadores respondem a tais exposições. Indivíduos com estes genótipos poderão 
exibir um maior risco de desenvolvimento de problemas no neurodesenvolvimento, como a PEA. Quando 
cruzamos o genótipo dos probandos com a exposição reportada, verificamos que os probandos portadores 
de alguns dos polimorfismos podem ter sido expostos aos produtos químicos aos quais são sensíveis durante 
períodos críticos do desenvolvimento neurológico. 
!
Discussão: Os nossos resultados demonstram que se podem obter dados importantes da combinação do 
ELEAT com informação genética. Apesar de extenso, o questionário relevou-se uma ferramenta útil para a 
recolha de informação relativa à exposição ambiental. A genotipagem de vários polimorfismos comuns na 
população geral, mas que poderão afetar a metabolização de vários fatores ambientais, poderá constituir 
uma abordagem apropriada para a identificação de indivíduos em maior risco de desenvolver PEA. Uma 
vez que a população geral está regularmente exposta a alguns dos produtos químicos analisados, os fatores 
genéticos desempenham um papel crucial no aumento da suscetibilidade e, portanto, podem levar a 
consequências negativas, como o aumento do risco a PEA. Algumas variantes investigadas neste estudo 
ainda não foram relacionadas com a PEA, mas têm o potencial de contribuir indiretamente para o 
desenvolvimento da patologia. Este estudo piloto é um passo importante para futuros trabalhos de 
investigação que pretendam usar o ELEAT para identificar fatores de risco ambientais para a PEA. Tais 
estudos deverão incluir uma amostra populacional grande e igual número de controlos, a fim de obter poder 
valor estatístico para calcular o efeito combinado de exposições ambientais e suscetibilidade genética. 
!
Conclusão: Apesar da sua limitada dimensão, o estudo aqui apresentado é de particular relevância pois é 
um ponto de partida para o estudo conjunto de fatores genéticos e não-genéticos na PEA. Dado que o 
contacto com fatores ambientais poderá ser modificado de forma a evitar a exposição por indivíduos 
particularmente suscetíveis, o estudo de fatores de risco ambientais é de extrema importância. Em 
conclusão, a integração de informação recolhida através do ELEAT com informação genética poderá 
contribuir para a compreensão das interações gene-ambiente e para o desenvolvimento de estratégias 
preventivas para a Perturbação do Espetro do Autismo.!
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1.1 AUTISM SPECTRUM DISORDER 
Autism Spectrum Disorder (ASD) is a pervasive and clinically heterogeneous neurodevelopmental 
disorder characterized by deficits in social communication and interactions skills, and repetitive and 
stereotyped behaviours. Individuals with ASD may be overly dependent on routines, highly sensitive to 
changes in their environment, or intensely focused on unusual item parts (American Psychiatric 
Association, 2013). The symptoms vary from person to person, ranging from high-functioning to low- 
functioning individuals. One of the important changes in the fifth edition of the Diagnosis and Statistical 
Manual of Mental Disorders (DSM-5) is that the subgroups in Autism Disorder presented in DSM-4 were 
merged (Kulage, Smaldone, & Cohn, 2014). Therefore, the term ASD is currently used to define a broad 
concept of autism, manifested as a spectrum of behavioral, cognitive, and linguistic problems that include 
autistic disorder, Asperger syndrome, and pervasive developmental disorder not otherwise specified 
(PDDNOS) (American Psychiatric Association, 2013). 
ASD is usually diagnosed during early childhood, around 2 to 3 years of age. Early symptoms such 
as failure to respond to one’s name, reduced interest in social interaction and delayed babbling are common. 
One of the key features that hinders social interactions is the difficulty of seeing things from another 
person’s perspective, and therefore, difficulties in interpreting social cues (What Are the Symptoms of 
Autism? 2018; American Psychiatric Association, 2013). 
ASD occurs in all social, racial, ethnic and socioeconomic groups, with a prevalence of about 10 
out of 10,000 children in Portugal (Oliveira et al., 2007). In terms of global prevalence, studies in different 
countries estimate that the median ASD prevalence is of 17/10 000 (Elsabbagh et al., 2012). Higher 
prevalence rates in boys compared to girls are consistently observed, with a male to female ratio of 4:1 
(Werling & Geschwind, 2013). 
This disorder has significant caregiver, family and financial burdens, and lifelong impact to the 
affected individuals (Van Heijst & Geurts, 2015). There is no treatment for autism, but as children grow up 
and undergo therapy, symptoms may lessen and become milder. Early behavioral therapies are 
recommended as these have been shown to have more benefits. Intervention can involve behavioral 
treatments, medicines or both. ASD often appears with other comorbidities, such as seizures, intellectual 
disability, attention deficit hyperactivity disorder, and gastrointestinal distress. Addressing these conditions 
can improve attention, learning and related behaviors (American Psychiatric Association, 2013). 
ASD is a very complex disorder, and despite much research, its cause is still not evident. In the 
past, studies have mostly focused on the role of genetic factors, but it is becoming more apparent that non-
genetic factors are substantial players too. Since genetic factors alone are not sufficient to explain autism 





1.2 GENETICS & HERITABILITY 
The initial heritability estimates for ASD were very high (Sandin et al., 2017), prompting many 
research groups to search ASD genes. Nowadays, ASD is recognized to be genetically heterogeneous, 
therefore making it a complex disorder to study. However, technology advances have allowed for 
substantial progress in gene discovery. Common disease common variant (CDCV) used to be the dominant 
theory held in genetic studies of ASD. It was a common belief that, since most living humans come from 
the result of a rapid expansion of the human population, they share a substantial amount of genetic variation 
called common variants (>1%). Accumulation of common variants of low effect is the likely explanation 
for a majority of ASD cause. In other words, common variants are present in all human populations and 
control for normal phenotypes, but in particular combinations, they may result in the abnormal phenotypes 
of ASD, therefore increasing social and language dysfunctions. On the other hand, recent results from 
genetic investigations have shown the important contribution of rare genetic variants (<1%) in addition to 
common variants (Geschwind & State, 2015).  
The study of rare and de novo variants has brought about a dramatic progress in ASD genetic 
research during the past decade. The Human Gene Module from the Simons Foundation Autism Research 
Initiative (SFARI), an online database that includes a large collection of genes implicated in autism. Genes 
are divided into different categories depending on their scores. Currently, high confidence syndromic genes, 
with category 1 score, include: ADNP, AIRD1B, ASXL3, CHD2, CHD8, DYRK1A, KMT2A, NAA15, POGZ 
and SHANK3, which contain rare genetic variants. Variants found in ASD subjects include: de novo 
frameshift variants in the ADNP gene, de novo loss of function variant and a missense variants in the NAA15 
gene, de novo deletions within the ARID1B gene resulting in reduced transcript expression, and de novo 
loss of function variants in the DYRK1A gene. Additionally, other genes in the database such as MTF1, 
ESR1, ADORA2A, SHANK3 among others are also targeted by common variants. This reinforced the 
importance of studying both types of variants in ASD (SFARI Gene, 2018). 
On account of different heritability studies, it has become apparent that ASD onset could be due to 
several different genetic factors variations. That is, that a proportion of ASD phenotype variance can be 
explained by genetic factors. However, the level of heritability is still debated. A recent twin study 
performed in Sweden estimated that ASD heritability was 83% (Sandin et al., 2017). This estimate is higher 
than that of the California twin study, where the authors estimated a genetic heritability of 38%, and a 58% 
estimate for shared environmental factors (Hallmayer et al., 2011). These results lead the researchers to 
conclude that, although genetic factors also play an important role in ASD, a significant proportion of the 
variance in liability can be explained by environmental factors common to twins (Hallmayer et al., 2011). 
This study underlines the importance of non-genetic environment factors in the development of ASD. 
Although, during the years, different studies have put ASD heritability on the range of 38% to 90%, there 
is still a meaningful percentage that can be explained by environmental factors (Sandin et al., 2017).  
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1.3 ENVIRONMENTAL FACTORS AND AUTISM SPECTRUM DISORDER  
Since there has been an accumulation of evidence pointing to the role played by environmental 
factors in ASD risk, a considerable number of studies have focused on this area, which was previously 
underexplored. As seen in figure 1, there are various mechanisms through which certain environmental 




Figure 1: Interactions between environmental and genetic factors that modulate the genome and epigenome of susceptible 
individuals. The grey boxes present environmental factors, the orange boxes present genetic factors. The blue boxes represent 
biological mechanisms. (adapted!from Koufaris & Sismani 2015) 
 
When mechanisms responsible for body homeostasis are debilitated, the interaction with potentially 
hazardous environmental factors may result in internal dysregulation such as abnormal immune activation, 
increased oxidative stress, as well as genomic instability. It has been established that immune system 
dysregulation, including infections in early pregnancy, prenatal maternal inflammation, and increased 
neuronal inflammation, could be contributing factors for the development of ASD. This could be due to the 
fact that chronic inflammation can be a source of reactive oxygen species (ROS), thus contributing to 
oxidative stress. Moreover, because imbalanced cytokine release can disrupt neurophysiological 
neurodevelopment due to their ability to affect both development and function of the neuronal system. 
Factors that can trigger these immune responses include environmental exposures to toxins, allergens and 
infections, as well as failure from mechanisms that clear these xenobiotics from the body, such as metabolic 
enzymes (Koufaris & Sismani, 2015). 
Studies have also shown that environmental factors have the ability to affect epigenics. These are 
mechanisms that biochemically modify DNA or histones affecting gene expression, without changing the 
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DNA sequence (Modabbernia, Velthorst, & Reichenberg, 2017). Environmental factors associated with 
ASD that can affect these mechanisms include exposure to heavy metals, levels of dietary folate (Koufaris 
& Sismani, 2015), as well as maternal use of valproate, used primarily to treat epilepsy and bipolar 
disorders, due to its ability to inhibit histone deacetylase and interference with folic acid metabolism 
(Modabbernia et al., 2017). 
 
1.3.1 ENDOCRINE DISRUPTIVE CHEMICALS 
A category of environmental factors known to dysregulate optimal bodily functions, and that have 
been linked to the risk of ASD development are Endocrine Disruptive Chemicals (EDCs). According to the 
U.S Environmental Protection Agency, an EDC is “an exogenous agent that interferes with synthesis, 
secretion, transport, metabolism, binding action, or elimination of natural blood-borne hormones that are 
present in the body and are responsible for homeostasis, reproduction, and developmental process.” 
(Diamanti-Kandarakis et al., 2009). These substances can be either natural or synthetic, and result in 
modifying the systems that enable the organism to communicate with and respond to the environment. They 
affect: nuclear receptors, non-nuclear steroid hormone receptors, nonsteroid receptors (e.g.: 
neurotransmitters), and enzyme pathways (Diamanti-Kandarakis et al., 2009). ASD may be associated with 
increased sensitivity to EDCs, where vulnerability depends on one’s genotype: individuals who are more 
susceptible could have more serious reactions when exposed even to low doses of EDCs, which could result 
in increased risk of ASD due to abnormalities in brain development and in hormone levels (Koufaris & 
Sismani, 2015). 
Examples of EDCs include plastics (bisphenol A), plasticizers (phthalates), pesticides (DDT, 
chlorpyrifos), fungicides (vinclozolin), pharmaceutical agents, heavy metals, and chemicals used as 
industrial solvents/lubricants and their byproducts (PCBs, PBB, PBDEs) (Diamanti-Kandarakis et al., 
2009). Bisphenol A (BPA) is used in a wide variety of applications such as food-can lining and baby bottles, 
while alkylphenols, another type of phenol, is used products such as detergents and pesticide formulations 
(Yi et al., 2013). Due to its disruptive effects, the use of BPA in baby bottles has been banned in some 
countries, but it can still be found in alternative sources. Persistent Organic Pollutants, PCBs, are synthetic 
carbon-based chemicals that accumulate in the environment and in human tissues. Diet is their main source 
of exposure due to their ability to bioaccumulate in predatory fish and breast milk (Kalkbrenner, Schmidt, 
& Penlesky, 2014). There is a wide range of pesticides available in the market, characterized by different 
functions, such as insecticide, herbicide, fungicide, among others. Whereas in general they are all known 
to have toxic effects on humans; organophosphates (OP) and organochlorines (OC) have the most evidence 
of neurotoxicity, and therefore, are thought to increase the risk of ASD development. OC pesticides have 
been recognized to interfere with neurodevelopment due to their EDC properties, while OP pesticides 
restrict neurotransmission in both peripheral and central nervous system (CNS) by inhibiting 
acetylycholinesterase production in the brain, thus affecting synapse formation, axon transmission, cell 
maturation, and programmed cell death. Heavy metals such as lead and mercury have highly significant 
and consistent evidence of hindering neurodevelopment, resulting in damages such as the loss of IQ points 
and behavioral problems. The main source of exposure for lead is via inhalation, as a consequence of its 
diffusion into the air from the usage of leaded gasoline and paints, and via ingestion for mercury, due to the 
bioaccumulation of methylmercury in food (Kalkbrenner, Schmidt, & Penlesky, 2014). 
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Endocrine disrupting chemicals are also known to target neurotransmitters such as dopamine, 
norepinephrine, serotonin, and glutamate. This is important because it explains effects of EDCs on 
cognition, learning, memory, and other behaviors which can be related to ASD (Diamanti-Kandarakis et 
al., 2009). Twin studies have found that variation in alleles of the serotonin transporter gene at 17q11–q12 
are more frequent in individuals with autism (Tordjman et al., 2014). Following that these variants in 
individuals with ASD may attribute an increased sensibility to EDCs, which are known to target 
neurotransmitters such as serotonin, it could be predicted that their reaction to EDC exposure could be even 
more detrimental than that of an individual without such genetic variants. 
The role played by sex hormones in the development of ASD have been a subject of study as an 
attempt to determine the source of sex differences in autism. Due to the action of hormones during 
embryonic and early postnatal development, there is the masculinization of the brain through the presence 
of estradiol & testosterone, and feminization of the brain through the absence of steroid hormones for 
females in this period. Research has shown that PCBs, phytoestrogens, fungicides, pesticides, and other 
xenobiotics can disrupt brain sexual differentiation. When these disruptions happen during critical periods, 
they can lead to the development of disease later in life, such as ASD (Diamanti-Kandarakis et al., 2009). 
This hypothesis is supported by studies that found significant associations between SNPs in estrogen 
receptors & enzymes involved in testosterone metabolism and the development of ASD. Furthermore, it 
has been shown that elevated levels of sex steroid hormones in boys diagnosed with autism when analyzing 
amniotic fluid (Koufaris & Sismani, 2015). 
As seen above, the effects of EDCs on neurodevelopment can have dire consequences. However, 
controlling exposure to these chemicals has proven to be extremely difficult considering that, not only are 
there various sources for contamination, such as drinking contaminated water, breathing contaminated air, 
ingesting food, or contacting contaminated soil, but also because these bioaccumulate in the food chain, 
and some have a very prolonged life span, which allows them to migrate to areas where they were never 
produced, and sometimes are broken down into even more toxic compounds (Diamanti-Kandarakis et al., 
2009). Other xenobiotics may not act as EDCs, but use other mechanisms to increase ASD risk. 
1.3.2 METABOLISM 
Metabolism is a key mechanism  involved in degradation of xenobiotics, and it is a potential 
pathway thought to be disrupted in ASD: It is suggested that people who have defective xenobiotic 
metabolism will have increased sensitivity to certain environmental risk factors which can be easily 
processed by individuals with efficient metabolism. Xenobiotic enzymes are responsible for detoxifying 
and removing harmful chemicals from the body, primarily in the liver, but also in other parts of the body 
such as the brain. Polymorphisms affecting such enzymes have been associated with ASD (Koufaris & 
Sismani, 2015). These include polymorphisms in cytochrome p450 enzyme, responsible for metabolizing 
possibly toxic substances including pharmaceutical drugs, enzyme paraoxonase (PON1), involved in the 
removal of organophosphate pesticides from the body, and the metal-regulatory transcription factor 1 
(MTF1), involved in metal homeostasis in response to heavy metals (Koufaris & Sismani, 2015). 
The Cytochrome P450 enzyme family has been especially studied due to its essential role in 
metabolism. In cells, Cytochrome P450 enzymes can be found in the mitochondria, where they are usually 
involved in the synthesis and metabolism of internal substances. They can also be found in the endoplasmic 
reticulum, where they generally metabolize external substances, mainly medication and environmental 
pollutants (Cytochrome p450, 2018). There are two phases in metabolization, and Cytochrome P450 
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enzymes are the main enzymes involved in phase I reactions. Phase I reactions include hydroxylation, 
reduction and oxidation, followed by phase II reactions such as glucuronidation, sulfation, acetylation and 
methylation. Another justification for the importance of these enzymes comes from the essential role they 
play in the metabolism of medications: cytochrome p450 enzymes are divided into families and subfamilies 
according to similarities in function, and cytochromes families 1 to 3 are responsible for the significant 
portion of 70% to 80% of all phase I dependent drug metabolisms, and also participate in the metabolism 
of a large number of xenobiotic chemicals (Wijnen et al., 2007). In general, 90% of metabolic activity fall 
on six enzymes: CYP1A2, CYP3A, CYP2C9, CYP2C19, CYP2D6 and CYP2E1, showing the crucial role 
played by this family of enzymes in metabolism, and how imperative they are (Wijnen et al., 2007). 
These family of enzymes is highly polymorphic, and each polymorphism will affect the efficiency 
of one’s metabolization. This is also very important in the world of medicine, since these enzymes play 
such a vital role in the metabolization of pharmaceutical drugs. Depending on the polymorphism, and 
individual can be a ultra-extensive metabolizer (UEM), extensive metabolizer (EM), intermediate 
metabolizer (IM) and finally a poor metabolizer (PM), all according to the speed and efficiency of their 
metabolization (Wijnen et al., 2007) .A PM will have much slower enzymatic activity compared to a EM; 
since the enzymes in a PM work slower, this person will have more of the drug’s active ingredient present 
in the body for longer period of time, whereas the EM will have less of the active ingredient and for a 
shorter period of time. Consequently, the polymorphism in Cytochrome P450 enzymes can affect 
medication dosage necessary. If the drug is slowly metabolized, less will be needed to achieve the desired 
effect, while more will be needed if it is metabolized fast (Cytochrome p450, 2018). This is crucial, as it 
may result in drug toxicity in an poor metabolizer if one is administered a high drug dosage or multiple 
drugs that are metabolized by the same cytochrome, and thus compete with each other (Wijnen et al., 2007). 
The same mechanism applies to other xenobiotics such as environmental toxins. Therefore, it is 
believed that cytochrome p450 enzymes may be involved in the mechanisms which lead to an increased 
risk of ASD development: Poor metabolization of xenobiotics may lead to the accumulation of toxic 
substances in the body, which can therefore have negative effects and interfere with fetus’ 
neurodevelopment. Thus, polymorphisms that affect the function of xenobiotic enzymes can make certain 
individuals more sensitive to environmental ASD risk factors (Koufaris & Sismani, 2015). 
1.3.3 PHYSIOLOGICAL BARRIERS 
The human body is protected by different permeability barriers such as the blood- brain barrier 
(BBB), the placental, intestinal and airway barriers that control our contact with external factors. The 
blood- brain barrier (BBB) plays an important role in CNS defense by limiting the entree of circulating 
solutes, macromolecules, and cells that could negatively impact neuronal activity (Fiorentino et al., 2016). 
The placenta, apart from the exchange nutrients and waste products between maternal and fetal 
circulatory system, it also protects the fetus from external chemicals (Gude, Roberts, Kalionis, & King, 
2004). The intestine acts as a selectively permeable barrier permitting the absorption of nutrients, 
electrolytes and water, while defending the body from toxins and antigens ( Groschwitz & Hogan, 2009). 
Finally, the airway barrier is responsible for clearing of inhaled pathogens, allergens and matter without 
inducing inflammation and maintain tissue homeostasis (Ganesan, Comstock, & Sajjan, 2013). It has been 
hypothesized that the malfunction of such barriers, can increase the risk of ASD development. Since 
chemicals have to pass by several of these obstacles before reaching the fetus’ brain, they play a crucial 
role in protecting the fetus from the harmful substances that the mother may be exposed to: chemicals 
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have to cross several barriers such as the placental and blood barrier in order to gain access to the 
developing brain. While later in life, after birth, their protection will depend on skin, airway and intestinal 
barriers (Carter, 2016). 
A study where genes previously associated with ASD were analyzed and related to barriers, 
found that a large number of these genes were placed and enriched in barriers and detoxification 
processes. Some of them were localized in the lateral ventricle, a cavity of the brain where xenobiotics 
and endogenous waste are eliminated from the cerebrospinal fluid to prevent accumulation in the brain. 
They were also highly enriched in blood-brain barrier, lung, skin, airway, respiratory cilia proteome 
datasets. Such results were also found in the liver, kidney and intestinal regions, which justify common 
ASD comorbidities such as gastrointestinal pathologies, as well as reports of impaired liver and kidney 
function (Carter, 2016). The significant enrichment of ASD genes in the intestine supports the hypothesis 
that inappropriate antigen trafficking through a damaged intestinal barrier, resulting in the passage of 
these antigens or immune-activated complexes through a permissive blood–brain barrier, can be part of 
the chain of events leading to neuroinflammation and thereby the development of disease. This increase 
of intestinal sensitivity to certain environmental factors explain why a controlled diet is recommended to 
patients with ASD. Many ASD patients experience gastrointestinal symptoms and dysfunctions which 
affect gut permeability, such as permeability to food antigens derived from partial digestion of wheat and 
cow’s milk, make ASD sufferers more sensitive to what they eat (Fiorentino et al., 2016). Genes 
associated with ASD are also enriched in reproductive tissues such as the endometrium and the cervix, 
which play vital roles against infectious agents, but also against industrial pollutants that may have toxic 
effects on reproductive tissues. Therefore, if these barriers do not function properly, there is an increased 
chance of maternal infection during pregnancy, which several studies have linked to increased risk of 
ASD development in offspring. While ASD genes expressed in the brain are important for 
neuropathological effects, these expressed and enriched in the barrier functions, specially BBB, are also 
extremely important because their allocation is very relevant to the many pollutants related to ASD 
(Carter, 2016). 
An example of ASD associated genes related to barrier functions are: transporters SLC1A1 
(glutamate) SLC19A1 (folate) SLC6A3 (dopamine) SLC6A4 (serotonin) SLC6A8 (creatine), and pumps 
ATP1A1, ATP10A which regulate chemical and ion entry at the cell membrane, placing the genes at an 
interface between environment and effect. Involved in placental function there is folate transporter 
(SLC19A1), as well as dihydrofolate reductase (DHFR) and 5,10-methylenetetrahydrofolate reductase 
(MTHFR), all involved in processing folate, an essential factor for embryonic development. As well as 
placentally localised genes like adenosine receptor (ADORA2A), Acetyl- cholinesterase (ACHE), and 
synaptic scaffold protein SHANK2. Dyslexia susceptibility 1 candidate 1 (DYX1C1), is involved in the 
regulation of respiratory cilia that sweep mucus, debris and toxic particles away from airways. And finally, 
genes such as glutathione peroxidase (GPX1) and transferase (GSTM1) and Paraoxonase 1(PON1) which 
are directly involved in detoxification processes such as that of heavy metals and organophosphate 
pesticides, respectively. All mechanisms previously associated with ASD development (Carter, 2016).  
1.4 PRENATAL, PERINATAL & NEONATAL RISKS 
Seeing as ASD has an early onset development , it comes as no surprise that a number of studies 
have been focused on maternal lifestyle, with attempts to correlate prenatal factors to ASD development. 
A study found that by every 10 year increase in maternal and paternal age, the increase of ASD risk in the 
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offspring is that of 18% and 21% respectively. In addition to this, it has also been hypothesized that the 
increase in ASD risk may be attributed to the accumulation of toxins, such as persistent organic pollutants 
(PCBs) and EDCs, in the body since it is probable that older parents lived in times prior to chemicals bans 
and experienced more years of accumulation (Kalkbrenner et al., 2014). 
In terms of medication used during pregnancy, pharmaceutical drugs such as valproate has been 
associated with ASD in offspring on account on its effect on neurodevelopment (Kalkbrenner et al., 2014). 
It is also important to note that different studies have suggested the incidence of drug metabolism alteration 
during pregnancy. It is a well-known fact that hormone levels change during pregnancy: there is an increase 
of female hormone concentrations in the plasma, such as progesterone and estrogens. A study investigating 
the relationship between this increase in hormone level and the expression of drug-metabolizing enzymes, 
found that these hormones are capable of modulating expression and/or activity of certain drug-
metabolizing enzymes (Jeong, 2010). On account of reported clinical changes during pregnancy, shown in 
table 1, researchers hypothesized that female hormones are possibly responsible for certain cytochrome 
p450 enzymes alterations during pregnancy. They found that estradiol up-regulates expression of CYP2A6, 
CYP2B6, CYP3A4 and UGT1A4, but down-regulates CYP1A2, while progesterone up-regulates UGT1A1 
(Jeong, 2010). 
Table 1. Altered drug  metabolism during pregnancy: Elimination rates of drugs (in mother) metabolized by UGT1A4, UGT2B7, 
CYP2A6, CYP2C9, CYP2D6 and CYP3A4 are increased, whereas those of CYP1A2 and CYP2C19 substrate drugs are decreased.  
(adapted from Jeong, 2010) 
CYP Direction of activity change Clinical evidence 
CYP1A2 Decrease Decreased apparent clearances or increased metabolic ratios of caffeine, theophylline, olazapine, and clozapine 
CYP2A6 Increase Increased clearance of nicotine 
CYP2D6 Increase Increased apparent clearances or decreased metabolic ratio of fluoxetine, citalopram, metoprolol, and dextromethorphan 
CYP2C9 Increase Increased apparent clearances of phenytoin and glyburide 
CYP2C19 Decrease Increased metabolic ratio of proguanil 
CYP3A4 Increase Increased apparent clearances of midazolam, nifenidine, and indinavir 
UGT1A4 Increase Increased apparent clearances of lamotrigine 
 
Air pollution has also been associated with ASD: a study found elevated risk for ASD in adjusted 
analyses of the top quartile of exposure to chlorinated solvents, heavy metals, diesel particles and other 
individual compounds (Lyall, Schmidt, & Hertz-Picciotto, 2014). Although controlling exposure to such 
pollutants may be challenging, their interaction with a developing fetus may have dire consequences; metals 
are capable of crossing the placenta and blood-brain barrier, accumulate in developing brain and interact 
directly at the cellular level through a variety of mechanisms and causing reactive oxygen species 
(Kalkbrenner et al., 2014). Exposure may be due to residential proximity to freeway, traffic-related air 
pollution, high levels of modeled air pollution at home, etc. (Tordjman et al., 2014). Another study on air 
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pollution, with controlled sociodemographic factors, linked residence proximity to a freeway at the time of 
delivery with nearly a doubling in odds of having a child with ASD (Lyall et al., 2014). On the other hand, 
due to tobacco’s renowned harmful effects, studies have explored its relationship to ASD but no significant 
association linked to maternal smoking during pregnancy has been found (Kalkbrenner et al., 2014). 
Studies investigating prenatal factors are difficult to conduct and interpret since it is very unlikely 
that these factors are independent environmental risks. For example, studies liking maternal immigration to 
ASD are more likely to be due to lack of immunity against infectious agents in the country the mother gives 
birth in, and also due to maternal stress due to immigration itself that could be associated with social 
economic factors (Gardener, Spiegelman, & Buka, 2009). As for the relations found between gestational 
bleeding and ASD, this might be due to hypoxia, which in turn may be related to fetal distress, maternal 
bleeding, umbilical-cord complications, low Apgar, among other complications (Tordjman et al., 2014; 
Gardener et al., 2009). It is also challenging to study medication use due to the variety of medications used 
during pregnancy. 
In terms of prenatal environmental factors that seem to decrease the risk of ASD development, 
studies with folic acid have produced the most consistent results. In a case-control study, consumption of 
prenatal vitamin supplements near the time of conception was associated with about 40% reduction in risk 
for ASD (Lyall et al., 2014). Yet another study found a lower incidence of ASD in children whose 
mothers received prenatal folic acid supplementation around the time of conception (64/61 042 or 0.10%) 
than in children whose mothers did not take folic acid (Tordjman et al., 2014). Therefore, it is suggested 
that maternal use of folic acid supplements during pregnancy could significantly reduce the risk of ASD 
in children as compared to those without folic acid supplementation (Wang, Li, Zhao, & Li, 2017). In 
addition to this, vitamin D has been shown to play a role in ASD onset. 25OHD is the metabolite used to 
measure levels of vitamin D, and studies shave show that lack or deficiency of 25OHD during gestation is 
associated with an increased risk of ASD development (Vinkhuyzen et al., 2017; Rebecca J. Schmidt et 
al., 2015; Cieślińska et al., 2017; Chen, Xin, Wei, Zhang, & Xiao, 2016). A study has found that, 
compared with individuals with sufficient concentrations of 25OHD at mid-gestation, those that were 
deficient had a more than twofold increased risk of ASD (Vinkhuyzen et al., 2017). Yet, another study 
also found negative association between risk of ASD and maternal 25OHD serum, but on the first 
trimester: they found that mothers in autistic children had significantly lower serum levels of 25OHD than 
mothers of typically-developing children (Chen et al., 2016). Thus, studies suggest that maternal levels of 
vitamin D during gestation can affect fetus’ neurodevelopment.  
It appears that no specific factor has been consistently validated as an independent environmental 
risk factor for ASD (Tordjman et al., 2014). Therefore, future environmental studies need to include 
combinations instead of trying to single out risk factors. 
1.4.1 BREASTFEEDING AND EDCS 
Special attention has been attributed to breastfeeding since this is the main source of nutrition of a 
newborn, and also on the account that colostrum has been recognized as a font of EDC contamination since 
this is one of the most effective methods of excreting lipophilic chemicals (Kalkbrenner et al., 2014). A 
study that measured phenols in colostrum, found elevated levels of BPA being transmitted from mother to 
infant. This is worrying due to the fact that, unlike adults, newborns do not have fully developed 
detoxification enzymes, and in addition to this, it is believed that they have a higher body burden 
considering their low body weight and high susceptibility. Thanks to a questionnaire, the study also linked 
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this increase in colostrum BPA with maternal consumption of dairy products. This is believe to be a result 
of the packaging and storage processes which put the food in direct contact with these materials, and leads 
to contamination (Yi et al., 2013). These results are important to ASD studies, considering that EDC has 
been linked to neurodevelopmental damage, and therefore increase of ASD risk. 
 
1.5 ELEAT 
The Early Life Exposure Assessment Tool (ELEAT), originally developed in California by researchers 
of University of California Davis, is a questionnaire that aims to assess environmental exposures that have 
been associated with ASD development. It allows for an indirect approach given that it uses measurements 
of exposures in specific microenvironments (e.g. home) and human activity pattern (e.g. maternal lifestyle) 
data to predict levels of fetal/infant exposure. For example, to measure vitamin D synthesis, the mothers 
were asked about the number of hours spent outside during sunny periods while pregnant, instead of a direct 
measurement of vitamin D levels in plasma. Indirect exposures, such as this one, are used frequently on 
account that they require less resources than the assessment of direct exposures. 
The long-term goal of this questionnaire is to assess the role of environmental exposures during early 
life windows of susceptibility relevant to ASD. However, as previously stated in Environmental Factors 
and Autism Spectrum Disorder section, is has been suggested that gene-environment interactions play an 
important role in ASD onset. Thus, to our understanding, in order to complement the ELEAT, there is the 
need to also address genetic factors that may modulate our organisms’ response to external factors.  
It is important to mention that, although different countries have been working with this tool, to our 
knowledge no results have been published to date.  
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2. GOALS AND STRATEGY 
The pilot study here presented is part of a broader project and its main goal is to contribute to the better 
understanding of gene-environment interactions in ASD. For this, from a sample of children with the 
disorder, we aimed to collect information regarding early environmental exposure, through the application 
of the ELEAT questionnaire, in addition to analyzing genetic data. Thus, by joining these two 
complementary approaches, the objectives of this pilot study are to: 
i.! Define the type of data that can be obtained from the ELEAT questionnaire and how such data can 
be analyzed and interpreted; 
ii.! Define how results regarding environmental exposure obtained through the ELEAT can be related 
to genetic information collected from the same subjects; 
iii.! Identify links between environmental exposures and genetic variants that can be further explored 
in gene-environment studies in ASD.  
 
In order to reach these goals, the following strategy (figure 2) was applied: 
•! Contact parents of children diagnosed in ASD and invite them to participate in the project by filling 
out the ELEAT. 
•! Collect biological samples from the affected children, for DNA extraction.  
•! Analyze ELEAT questions in order to know what environmental factors are being investigated in 
each question. 
•! Select genes that interact with the environmental factors investigated in ELEAT. 
•! Select polymorphisms that may interfere with gene function, and consequently, disrupt organisms’ 
response to exogenous factors. 
•! Investigate if these genetic variants were present in the sample of probands. 
•! Investigate whether probands carrying these variants were exposed to the specific environmental 









































































Figure 2. Scheme of strategy used to achieve the study’s objectives 
ASDEU project Contact parents of children with ASD 
Collect biological samples 
(blood or saliva) Fill ELEAT 
See what 
environmental factors 
are being investigated 
in each question 
 
Select genes that 
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environmental factors 
Select polymorphisms 
that may interfere with 
gene function 
Identify the genetic 
variants present in the 
sample of probands 
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3.1.1 ASDEU PROJECT 
Participants for this study were recruited from the Autism Spectrum Disorder in the European Union 
(ASDEU) project. This aimed to investigate the prevalence of autism in 12 countries in the European Union, 
including Portugal, which was finalized in 2017. For this project,  teachers of  primary schools located in 
the Center Region of Portugal, were invited to fill in a questionnaire where they should nominate children 
in their class presenting characteristic ASD  behaviors, such as: social awkwardness, intense interest in just 
a few topics or activities, reduced  flexibility, tendency to insist on certain rules and routines, among others. 
The Central Region was the area chosen for this project considering that it includes 31.3 % of mainland 
Portugal and 23.7% of its population, and also on account that the Pediatric Hospital of Coimbra, which 
works closely with our department in INSA (National Health Institute Doutor Ricardo Jorge), is the 
reference pediatric hospital in that region and has clinical registers of a large percentage of ASD children. 
Moreover, the selected region includes both urban and rural neighborhoods, being an effective proxy for 
the whole Portuguese population and the whole array of possible environmental exposures.  
As part of the ASDEU project, after the children were nominated by the teachers and the parents signed 
the informed consent, children were evaluated in the Hospital of Coimbra for the ascertainment of ASD, 
by an experienced clinical team. The diagnosis was carried out by applying ADOS, ADIR, Vineland, WISC 
III or Griffinths, thus, resulting in 54 diagnosed children. Simultaneously, biological samples were 
collected. However, some families  had already been recruited for  previous projects and, consequently, we 
already had their biological samples, which were processed by INSA and stored with anonymized codes. 
It was from this list of families that parents were contacted and invited to be part of the ELEAT project. 





The ELEAT’s objective is to understand how environmental risk factors can influence ASD 
development. 
 This tool is divided in 10 modules: Demographic Information, Maternal Conditions/Medical 
Interventions, Breastfeeding and Child Diet, Maternal Diet, Supplements, Lifestyle, Home and 
Environment, Environment, and Occupation and Exposures, and Instrument Evaluation.  This questionnaire 
is constituted by 259 items (some may be skipped with gateway questions), corresponding to 80 pages, 
which intend to assess 3 different periods: it examines maternal exposure to exogenous factors from 3 
months before conception to the first year of the child’s life. Therefore, covering crucial phases of early 
neurodevelopment, with each module analyzing different sources of exposure.  
The questionnaire, which is to be filled by the mothers of the children with ASD, was translated into 
Portuguese from the UK version due to the greater similarities in lifestyle compared to the US. For example, 
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the American ELEAT included questions regarding fish types that were not available in Portugal, as well 
as housing typologies. 
In addition to the paper version, an online version was created in the RedCAP survey, a secure web 
application for building and managing online surveys and databases. Here the mothers were able to access 
the questionnaire through a link, and were given the option to save their answers and proceed filling it in 
later. This became the main filling method not only because it was more organized, but mainly because, 
seeing as the questionnaire is extensive, the fact that the mothers could save their answers and return to it 
later made it easier and more appealing due to busy lifestyles. However, the mothers had always the chance 
to fill out the questionnaire in paper version.  
After translation, the ELEAT was piloted in a group of mothers of typically-developing and ASD 
children, ranging from 1 to 8 years. All mothers had a university degree, and were between 35 and 44 years 
old.  
This was done with the objective of obtaining feedback from the mothers regarding the questionnaire, 
such as clarity, length and relevance of the questions. This was done by analyzing the last module of the 
tool, which consists of questions were the mothers can rate the instrument.  
3.3 PROCEDURE 
3.3.1 CONTACTING PARENTS 
For this project, we contacted a total of 54 parents (with children diagnosed with ASD) through the 
phone, and after a brief explanation about the project and its goals, they were invited to participate by filling 
the ELEAT. The parents who agreed provided us with their email, to which we sent a link for the ELEAT’s 
online version, along with an explanation about the steps to take. After the initiating the filling of the tool, 
the website attributed an access code which allowed mothers to return to the application and continue the 
filling out process. After a period of time of inactivity, the parents who did not fill the questionnaire were 
contacted again as a reminder: some were contacted through the phone, while the ones who had started 
filling the questionnaire, but did not conclude it, were sent an email with their access code and offered help 
to clarify any questions. This process had to be repeated several times, and for those who had incomplete 
questionnaires we offered phone assistance: to fill the questionnaire with the parents by asking them 
questions through the phone, and clarifying any doubts. 
As three mothers did not have email, they were unable to access the ELEAT online. Thus, we 
offered personal assistance to them, by  traveling to their homes in the center region of Portugal and help 
them fill out the questionnaire. Such travels were necessary, not only because we could not send the link of 
the online version, but also to ensure that there were no doubts regarding the questions. 
3.3.2 COLLECTION OF SAMPLES 
Biological samples were only collected from the children whose mothers filled out the questionnaire 
but did not have samples collected at the moment of diagnosis. This was done using swab kits from 
iSWABtm. A total of 12 parents were contacted though the phone and asked if they were willing to provide 
a biological sample, to which all of them agreed. They were given two options: we could travel to their 
houses and collect the sample ourselves, or we could send them the swab kit by mail with clear instructions 
on how to use them, which they could then send back to INSA in a prepaid package. All parents preferred 
to collect the sample themselves and send it back to us. 
! 15!
After a certain period of time, the parents who had not returned the samples were sent an email to know 
if the kit had not arrived, or if they were having trouble with the process, to which we offered our assistance.  
3.3.3 SELECTION OF ELEAT QUESTIONS 
As the ELEAT questionnaire is very extensive and, as we intended to focus our research, we 
selected a total of 156 of questions (without counting the sub-questions) to further analyze. We chose 
questions that allowed us to more directly assess probable exposures to environmental toxins relevant to 
ASD, which have been well reported  in literature. Additionally, we also selected questions that evaluate 
exposure to other environmental factors which  are hypothesized to be relevant to ASD, such as the intake 
of certain supplements like folic acid, and vitamin D during the period covered by the ELEAT. As addressed 
ahead, it was also important that the organism’s response to the evaluated factors could be clearly related 
to specific genes. In summary, we selected questions where: 
•! The rationale and environmental factor being analyzed was sufficiently clear; 
•! Most of the environmental factors have been associated with ASD risk; 
•! Specific genes have been related to these environmental factors. 
3.3.4 PRESENTATION OF ELEAT RESULTS 
Out of the 54 contacted parents, a total of 20 mothers filled the questionnaire. Seeing as some 
mothers left questions unanswered, percentages were always calculated based on the total number of 
answers to each selected question. The questionnaire had a number of sub-questions which were indicated 
only for mothers who answered “yes” in the main question. E.g.: Module B, question 4: “Did you feed your 
child with infant formula?”. Only the mothers who answered positively were to move on to question 4.c. 
“What type of formula did you use?”, while the other mothers would move to question 5. For this reason, 
the results presented in the sub-questions are out of the number of mother who responded affirmatively in 
the main question. 
3.3.5 SELECTION OF GENES AND POLYMORPHISMS: 
The choice of genes to be tested was based on available knowledge from literature 
 
i. Genes involved in the activity of environmental factors 
After compiling a list of the environmental factors being assessed in each of the selected questions, we 
searched for genes involved in the activity or regulation of barriers’ permeability to such factors. For that, 
we used the Comparative Toxicogenomics Database (CTD), a manually curated platform that provides 
information about interactions between chemicals and gene products, and their relationships to diseases 
(Davis et al., 2017). The CTD was used in the following way: after obtaining the MeSH ID (a unique 
identifier assigned to each chemical by the Medical Subjects Headings (https://www.nlm.nih.gov/mesh/)!
for each factor, each ID was inserted individually in CTD, after which a txt file could be downloaded. This 
file included the genes this factor interacts with, which were repeated according to the number of published 
references supporting each interaction. Due to this repetition, we were able to assign higher support to genes 
more frequently referenced . As a result, each factor had a list of genes they interact with, and these were 
ordered from higher to lower number of references. The genes that were chosen were those with higher 
support.. 
From this list of selected genes, we chose to analyze functional polymorphisms; these are 
polymorphisms that disturb gene function by affecting the functionality of the produced protein. We 
selected those whose effect on protein has been well studied. In addition to this, we showed preference to 
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those that have higher population frequencies in order to increase the chances of finding them in a small 
sample. 
 
ii. Genes involved specifically in the activity of pharmaceutical drugs 
In order to select which genes involved in medications effects we should analyze, we started by 
exploring ELEAT’s Maternal conditions/Medical interventions Module, where each medication taken by 
the mothers was annotated. To find the active ingredients for each of these medications, we resorted to 
Infomed (http://app7.infarmed.pt/infomed/), the medication database of the website Infarmed, which 
contains information on human medication, namely the name of the medicinal products, active substances 
(INN / generic name), dosage, pharmaceutical form, among others. 
Next, the names of the active ingredients were inserted in the database PharmGKB: a 
pharmacogenomics knowledge resource with information about the impact of genetic variation on drug 
response (Altman, 2007). To collect the data we needed, we used the Clinical Annotations section which 
gave us information about variant-drug pairs, based on variant annotations in the database. Here we were 
able to identify the genes these medications interacted with, the specific polymorphisms that affect their 
function, as well as the type of effect they have: such as toxicity, efficacy, dosage, among others. 
Additionally, the level of evidence for each polymorphism was also listed. 
With this information, a table was created with medications’ name, their active ingredient, and the 
genes and specific polymorphisms they interacted with. From here, we excluded HLA (Human Leukocyte 
Antigens) genes due to their complexity, and polymorphisms that affected factors other than toxicity and 
efficacy (see attachment S1). This is because we were investigating toxic effects that medication and other 
environmental factors may have on the fetus if this carries a variation that makes it particularly vulnerable 
to that factor. Efficacy is included because, if a variation affects the efficacy of the metabolization of a 
medication, this can accumulate in the body and therefore become toxic. 
To clarify the genotype (the alternative allele) of each polymorphism, as well as the frequency in 
European (non-Finnish) and African populations, we used PharmGKB, GnomAD, a database that gathers 
exome and genome sequencing data from a wide variety of large-scale sequencing projects (Lek et al., 
2016), and ClinVar, a database belonging to NCBI which aggregates information about genomic variation 
and its relationship to human health (Landrum et al., 2014).  
Selected genes and genetic variants are displayed in table 2. 
3.4 LABORATORY PROCEDURES 
3.4.1 DNA EXTRACTION  
The DNA extraction of all the biological samples used was done at INSA, in the Health Promotion 
Department (DPS). 
From blood: 
The protocol used to extract DNA from blood was based on the “salting out” method described by 
D.K. Lahiri et al (1991). Since this is done from white blood cells, one of the first steps is to eliminate the 
erythrocytes followed by the deproteination, in order to be left only with white blood cells, which are 
nucleated and where genomic DNA can be extracted from human blood. For more details, please refer to 
attachment S2 for the full protocol. 
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From buccal swab sample: 
The protocol used for buccal swab samples was adapted (inhouse method) from “salting out” 
method described by D.K. Lahiri et al, skipping the elimination of erythrocytes steps, and using buccal 
mucosa instead of white blood cells. This protocol was applied on swab samples collected with iSWABtm -
DNA from mawi DNA Technologies, LCC.   
For more details, refer to attachment S3 for the full protocol.  
! 
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3.4.2 PRIMERS DESIGN 
By inserting the genomic coordinates of each polymorphism into the UCSC genome Browser 
(hg38/Human) website (https://genome.ucsc.edu/cgi-bin/hgc?g=getDna&i=hg38), we were able to find the 
genomic region that contains each polymorphism. Primer3 software was used to design forward and reverse 
primers. and to gather information regarding the melting temperature (ºC), and guanine-cytosine content 
(gc%).. In order to verify that there were no single nucleotide polymorphisms (SNPs) in each primer, we 
used the website SNP Check3. This informed us of any SNPs in the primer region and where exactly it was 
located so that the primer could be redesigned. Lastly, to confirm the specificity of the primers we used the 
BLAST tool from NCBI (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch). This gave 
us information on the whether the primers would bind specifically to the location we intended, with a 100% 
specificity. Primers used are displayed in table 3. 
 
Table 2: Genes, polymorphisms, variant annotations and analysis techniques used 
*UGT1A gene cluster (UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9). In gray are polymorphisms not 
found in PharmGKB.  
Gene Polymorphism Genotype Annotation
ABCB1 rs1045642 G > A Synonymous PCR and Digestion with MboI enzyme (PCR-RFLP) Jamroziak et al., 2002
ACHE rs2571598 C > T Intronic Sanger Sequencing
AHR rs4410790 T > C unannotated Sanger Sequencing
CYP1A1 rs2606345 C > A Intronic Sanger Sequencing Zhao et al., 2017
CYP2C19 CYP2C19*2 G > A Synonymous, creating an aberrant splice site Sanger Sequencing
CYP2D6*4 C > T Splice-acceptor region Sanger Sequencing
CYP2D6*6 del. T Frameshift Sanger Sequencing
CYP2R1 rs10741657 A > G Promoter Region PCR and Digestion with MnlI enzyme (PCR-RFLP) Ramos-Lopez et al., 2007
CYP3A4 rs2740574 C > T 5-prime promoter region Sanger Sequencing
GSTM1 GSTM1*0 homozygous GSTM1*0 GSTM1-null PCR (based on the length of PCR product)
HBB (internal control) NA NA NA Kendi Takeda et al., 2011
MTHFR rs1801133 C > T Missense PCR and Digestion with HinfI enzyme (PCR-RFLP) Chandra et al., 2009
OXTR rs2268498 T > C
promoter flanking region 
of OXTR
Sanger Sequencing
PLCG1 rs2228246 A > G Missense Sanger Sequencing
rs854560 A > T Missense Sanger Sequencing
rs662 T > C Missense Sanger Sequencing
SLC19A1 rs1051266 A > G Missense PCR and Digestion with CfoI enzyme (PCR-RFLP) Coppedè et al., 2014
TNFRSF11A rs1805034 C > T Missense Sanger Sequencing
UGT1A rs1042640 G > C 3 UTR Sanger Sequencing
rs10929303 T > C 3'UTR Sanger Sequencing Court et al., 2013
rs8330 G > C 3'UTR Sanger Sequencing Court et al., 2013
UGT2B15 rs1902023 A > C Missense Sanger Sequencing Alkharfy et al., 2017





PharmGKB PharmGKB & GnomAD Technique
! 18!
 
3.4.3. POLYMERASE CHAIN REACTION (PCR)  
For fragment amplification PCR we followed the protocol for Applied Biosystems AmpliTaq DNA 
Polymerase, and a mix was made with buffer, MgCl2, dNTPs, DNA Polymerase and H2O. The volume of 
the mix was calculated so that each  tube would receive 22ul. After this, 1ul of each primer specific to the 
polymorphism being analyzed was added to each tube. Finally, each tube received a 0,5ul of DNA, to make 
a final  volume of 25ul. 
The reactions were run under the following thermocycling conditions: 94ºC for 1 min; 30 cycles of 
94 ºC for 30 sec, 57-62 ºC for 30 sec (depending on the melting temperatures of each pair of primers) and 
72 ºC for 1 min, followed by 72ºC for 5 min and 4 ºC as resting temperature. For this, T3000 a 
programmable thermocycler from Biometra was used. 
The PCR products were ran in a 1.8% electrophoresis gel stained with 1.6ul of SYBR Safe DNA 
gel stain (Invitrogen). 5ul of each PCR product were mixed with 5ul of deposition solution and inserted 
into the wells  where they were then run in 90V for 40 minutes.  Afterwards, the PCR products were  purified 
by mixing 2ul ExoProStar x 5ul PCR product, and ran on the thermocycle under the following conditions: 
37 ºC for 15 min, 80 ºC for 15 min and lastly 4 ºC as resting temperature. 
!
Table 3. Forward and reverse primer sequences for each polymorphism being studied 
Gene RS PrimerForward PrimerReverse
ABCB1 rs1045642 TTGATGGCAAAGAAATAAAGC CTTACATTAGGCAGTGACTCG
ACHE rs2571598 AGTGCAGTGGTGCCATCATA GGGTCTTGCAGAGACAGAGG
AHR rs4410790 TGACTCCTATTGTTGTGAATAAAAGC CGGAAAAGCATTCTGAAGGA
CYP1A1 rs2606345 GGGAGATGGATGGTTCCTACCAC CCTCCTAAGGGTGGCTTGTCAGT
CYP2C19 rs4244285 (CYP2C19*2) CAACCAGAGCTTGGCATATTG TCACAAATACGCAAGCAGTCA
rs3892097 (CYP2D6*4) TCCTGAGCTAGGTCCAGCAG ATAGGGTTGGAGTGGGTGGT
rs5030655 (CYP2D6*6) TCCTGAGCTAGGTCCAGCAG ATAGGGTTGGAGTGGGTGGT
CYP2R1 rs10741657 GGGAAGAGCAATGACATGGA GCCCTGGAAGACTCATTTTG
CYP3A4 rs2740574 GGAAGAGGCTTCTCCACCTT CTGGGTTTGGAAGGATGTGT
GSTM1*0 TTTGCTCCGTTAGGATCTGG GAGGGTACTGCAGGAGACCA
GSTM1+/+ ACAGTGAGTGCCTGGTCTC TCAGGGCTGTAGCAGACTCT
HBB (internal control) CAACTTCATCCACGTTCACC GAAGAGCCAAGGACAGGTAC
MTHFR rs1801133 TGAAGGAGAAGGTGTCTGCGGGA AGGACGGTGCGGTGAGAGTG
OXTR rs2268498 AGGTCCTGTCCCTCTGGTTT TAGGCTGTCTCACGGGCTAC
PLCG1 rs2228246 GTGTCCCTTCCTGAGTTCCA GTCCTGGTCACCCCTACTCA
rs662 CAAATCCTTCTGCCACCACT AAGGATTGTATCGGCAGGAC
rs854560 TGGTTCAATGTAGACCGAAGAA TGGATCCACATCCTGCAATA
SLC19A1 rs1051266 AGCGTCACCTTCGTCCC TCCCGCGTGAAGTTCTTG
TNFRSF11A rs1805034 CCAAAGCACTGAACCACCTT CCCCCAATCCAGTGTAGAAA
UGT1A rs1042640 GCATAAATTAATCAGCCCCAGAGTGC CACCACCCACCAATTTCATAGCATC
rs10929303 GCATAAATTAATCAGCCCCAGAGTGC CACCACCCACCAATTTCATAGCATC
rs8330 GCATAAATTAATCAGCCCCAGAGTGC CACCACCCACCAATTTCATAGCATC
UGT2B15 rs1902023 GAGCTTGTTCAGAGGGGTCA CAAAACTGCATCTTTACAGAGCTT






3.4.4 SANGER SEQUENCING 
In order to prepare the samples sequencing, in each tube containing 1ul of PCR product, we added: 
0.5ul of sequencing buffer, 2ul of forward primer, 0.5 of BigDye terminator reaction mix, and 6ul of H2O. 
These were then run in the thermocycle with 96 ºC for 1 min; 25cycles of 96 ºC for 10 s, 58 ºC for 5 sec, 
55 ºC for 4 sec, and lastly 4 ºC as resting temperature. The tubes were then sent to a specialized group in 
the department of Human Genetics at INSA  to be sequenced by capillary electrophoresis. Chromatogram 
analyzes were done with Chromas software (Technelysium Pty Ltd). 
3.4.5. RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP) 
As shown in table 2, some of the selected polymorphisms were detected through RFLP. This is on 
account that for these polymorphisms this technique is well established. For all these variants PCR 
amplification was performed in a thermal cycler (T3000 thermocycler from Biometra) using the primers 
listed in table 3. Each PCR reaction contained 25ul of total volume (2.5ul PRC Buffer, 1.5ul MgCl2, 0.5ul 
dNTP mix, 1ul forward and 1ul of reverse primer, 0.3 of AmpliTaq DNA polymerase, 0.5ul of genomic 
DNA and 17.7ul of H20). 5ul of the PCR products were ran in in a 1.8% electrophoresis gel stained with 
1.6ul of SYBR safe dye. After checking for correct amplification, each mixture was subjected to 4 hour 
digestion at 37 ºC with the restriction enzymes referred in table 4, using CutSmart Buffer and BSA (Bovine 
Serum Albumin). Finally, genotypes were assessed by running the digested products, shown in table 4, in 
a 3% electrophoresis gel. 
 
3.4.6. PCR (DETECTION BASED ON THE LENGTH OF PCR PRODUCT) 
This protocol was used specifically for detecting GSTM1 genotype seeing as it is the only variant 
that is not a point mutation: the polymorphism corresponds to the deletion of the entire gene. Fragment 
amplification was done as described in Sanger Sequencing section, followed by electrophoresis in 1.8% 
agarose gel, which displayed different patterns depending on the genotype.  
For each of the 14 subjects two reactions were done: the first with primers specific for the upstream 
and downstream flanking regions of GSTM1 and the second with primers specific for a region inside 
GSTM1. In the gel (attachment S8) we used two wells per individual, with the first one corresponding to 
the deletion and the second one to the presence of the gene. Individuals homozygous for the deletion are 
expected to display a single DNA band of 433bp (in the first well), while individuals with no deletion are 
expected to display a band of 379bp (in the second well). Heterozygous individuals are expected to display 
both of these bands.  
As positive control, we used a pair of primers specific for a housekeeping gene. This was to ensure 
that amplification would happen for all subjects. The chosen gene was HBB (Hemoglobin Subunit Beta). 
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Gene rs Restriction Enzymes PCR product size (bp) RFLP digestion fragments
ABCB1 rs1045642 MboI 206 AA genotype: 206; GG genotype: 130+76; GA genotype: 130 + 76 / 206
CYP2R1 rs10741657 MnlI 288 GG genotype: 300; AA genotype: 2048+52; AG genoype: 248 + 52 / 300
MTHFR rs1801133 HinfI 198 TT genotype: 53 + 125; CC genotype: 198; CT genotype: 198 / 53+ 125
SLC19A1 rs1051266 CfoI 230 GG genotype: 125+105; AA genotype: 230; AG genoype; 230 / 125+105




4.1 ELEAT QUESTIONS & GENES 
After following criteria for the selection of ELEAT questions, and the respective genes that interact 
with the environmental factors being analyzed in each question, we obtained table 5. A total of 18 genes, 
comprehending 22 polymorphisms, were chosen to analyze. As it can be seen in the referred table, the 
selected questions assess exposure to different xenobiotics, from medications to environmental toxins (e.g. 
BPA, PBDEs, PCBs, heavy metals and pesticides). There is significative overlap between the factors 
processed by each of the selected genes, which was expected since most of those genes encode for key 
enzymes involved in biotransformation pathways. However, some genes are more specific to particular 
factors, such has MTHFR and SLC19A1 to folic acid, CYP2R1 and VDR to vitamin D and OXTR to oxytocin. 
Additionally, as previously referred, we prioritized the choice of exonic vs intronic polymorphisms, which 
can be seen by their higher frequency on the table. All of the selected polymorphisms are point mutations 
that change or delete a single nucleotide, apart from GSTM1*0 variant, which refers to the whole deletion 
of the gene. Most of the genes were selected due to their obvious role in the activity of environmental 
toxins. However, others (e.g. OXTR, PLCG1 and TNFRSF11A) were chosen due to the effect of certain 
polymorphisms in the effect of medications taken by the mothers’ who answered the ELEAT questionnaire.   
In table 6 is the functions of the selected genes and how these can be affected by the polymorphisms 
being studied. The genes have a wide variety of functions: some are receptors (e.g. AHR, OXTR, 
TNFRSF11A and VDR), transporters (e.g. ABCB1 and SLC19A1) Cytochrome P450 enzymes (e.g. 
CYP2C19, CYP2D6, CYP2R1) and other metabolizing-enzymes (i.e. GSTM1, MTHFR, PON1, UGT1A 
gene cluster, UGT2B15). Importantly, all of these genes have known roles in metabolization or 
detoxification of environmental factors or medications. As for the polymorphisms’ effect, most of them 
result in a reduced function of the protein, while some may lead to an increased activity. Such activity 
alterations may result in an improper response to external cues.  
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Table 5. Results obtained after  following criteria for the selection of ELEAT questions and genes that interact with the environmental factors 
being analyzed in each question. Module B: Breastfeeding & Child diet, Module M: Maternal Conditions/ Maternal Interventions, Module D: 
Maternal Diet, Module S: Supplements, Module L: Lifestyle, Module H: Home & Environment, Module E: Environment, Module O: Occupation 
& Exposure 
Questions Factor Being Studied Genes
Module H: Q.20, 22, 23 Module E: Q. 1, 3, 4, 5, 24-32, Module 
O: Q.15-22, 24, 25, 27







Module H: Q.13, 17, 18 Module L: Q. 10, 17 PAHs (benzo(a)pyrene) AHR
Module H: Q.20, 22, 23 Module E: Q. 1, 3, 4, 5, 24-32, Module 
O: Q.15-22, 24, 25, 27
Multiple xenobiotics such as phthalates, PBDEs, PCBs etc. UGT1A gene cluster 
Module B: Q. 5, Module D: Q.3 Bisphenol A UGT2B15
Module H: Q.20, 22, 23 Module E: Q. 1, 3, 4, 5, 24-32, Module 
O: Q.15-22, 24, 25, 27
Multiple xenobiotics such as phthalates, PBDEs, PCBs etc. GSTM1
PON1
ACHE
Module D: Q.26, Module H: Q. 11&12, Module E: Q.33, 
Module L: Q. 10, 17
Multiple xenobiotcis including  heavy metals and 
pharmaceutical drugs 
ABCB1







Module S: Q. 1, 2, 5 Folic Acid
Module L: Q. 3, Module D: Q.5, 25, 26 &29 Vitamin D; 25(OH)D
Module E: Q: 6-10 Module H: Q. 11, 21, Module O: Q.23 Organophosphate pesticides (i.e. chlorpyrifos)
Pharmaceutical drugs but specifically Acetaminophen 
Multiple xenobiotics but mainly pharmaceutical drugs






Table&7.&Gene&function& &Polymorphims&effect Table 6.  Function of the selected genes and effect of each of polymorphisms being studied  
Gene Gene Fucntion rs Change Polymorphism Effect Reference
ABCB1
Encodes for p-glycoprotein, an efflux transporter that limits the movement of 
multiple xenobiotics, such as heavy metals and pharmaceutical drugs, across the 
blood brain barrier and placenta
rs1045642 G>A
Allele A is associated with decreased expression of p-glycoprotein in some 
tissues, including the placenta, and therefore with diminished function
Brambila-Tapia 2003, Mollgard 
et al 2007, Miller et al 2009, 
Walker et al 2017
ACHE
Is an enzyme that hydrolyzes the neurotransmitter acetylcholine. This enzyme is 
also the primary target of inhibition by organophosphate pesticides. 
rs2571598 C>T
Allele T confers reduced acetylcholinesterase activity, which leads to reduced 
acetylcholine breakdown and thus less neurotransmission activity.
Reale et al 2018, Iossifov et al 
2015, Lionetto et al 2013
AHR
Receptor for many toxins. Upon binding of the toxin to AHR , there is an induction 
of xenobiotic-metabolizing enzymes such as cytochrome P450
rs4410790 T>C Allele C increases metabolism by inducing a higher expression of CYP s by AHR
Cornelis et al 2014, Moorthy et 
al 2015
CYP1A1
Enzyme involved in phase I metabolism of multiple xenobiotics, including PAHs, 
phthalates; many pharmaceutical drugs
rs2606345 C>A Allele A confers higher enzymatic activity to CYP1A1
Moorthy et al 2015, Sulem et al 
2011
CYP2C19
One of the most important CYP450 drug metabolizing enzyme in phase I 
expressed mainly in the liver
CYP2C19*2 G>A
Major loss-of-function SNP resulting in reduced enzymatic activity of CYP2C19 . 
Homozygous genotype (CYP2C19*2 /CYP2C19*2 ) are poor metabolizers, while 
CYP2C19*1/ CYP2C19*2  are intermediate metabolizers
Scott et al 2012
CYP2D6*4 C>T
Allele T causes a splicing defect that results in a low-activity protein. This is the 
main cause of CYP2D6 poor metabolizers in Caucasians
CYP2D6*6 deletion of T
Deletion of T is a frameshift mutation that results in a truncated, low-activity 
version of CYP2D6
CYP2R1
Enzyme that catalyzes the conversion of vitamin D to 25(OH)D, the main 
circulating vitamin D metabolite and the main ligand to VDR
rs10741657 A>G
Allele G confers low activity to CYP2R1 , and therefore leads to lower levels of 
25(OH)D
Schmidt et al 2015
CYP3A4
One of the predominant xenobiotics-metabolizing enzyme expressed in human 
liver with substrates including a large amount of pharmaceutical drugs, in addition 
to many xenobiotics
rs2740574 T>C
This polymorphism may lead to increased transcription of CYP3A4, which may 
result in higher levels of the enzyme
Basheer & Kerem 2015
GSTM1
Encodes for a glutathione S-transferase enzyme, which is involved in the 
detoxification of electrophilic compounds, including environmental toxins, by 




Deteletion results in reduced or no GSTM1  enzymatic activity, depending on the 
number of alleles deleted
James et al 2006, Buyske et al 
2006
MTHFR
Reductase involved in folic acid metabolism: catalyzes the conversion of 5,10-
MTHFR to 5-methyl-folate, the circulating form of folic acid, which is a substrate 
necessary for the remethylation of homocysteine to methionine 
rs1801133 C>T
Allele T results in reduced circulating folic acid due to lower MTHFR  activity. 
Compared to the most common genotype (C;C): 
Homozygous (T;T) individuals have ~30% of enzyme activity,
Heterozygotes (C;T) have ~65% enzyme activity
Liu et al 2011, James et al 2010, 
Schmidt et al 2012
CYP2D6
Major CYP450 drug metabolizing enzyme in phase I expressed in liver, gut, and 
brain
Zanger et al 2004
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Table 6(continued) Function of the selected genes and effect of each of polymorphisms being studied 
Gene Gene Fucntion rs Change Polymorphism Effect Reference
OXTR Encodes for a G-protein that functions as oxytocin receptor rs2268498 T>C
The C allele is associated with higher mRNA expression of OXT  receptor, which 
may reflect a reduced sensitivity to oxytocin
Montag et al
PLCG1
Involved in mast cell activation, which is important for neuroimmune activation, 
releasing histamine and other substances during inflammatory and allergic 
reactions. It also plays an important role in defense against pathogens, and 
blood–brain barrier function 
rs2228246 A>G
Allele G has been astudied in reation to risk of Angioedema (a form of severe 
swelling beneath the skin’s surface) when treated with acetaminophen  as 
compared to genotype AA. However, results reagrding the association are unclear.




SLC19A1 Folic acid transporter, involved in intracellular levels of folic acid rs1051266 A>G Allele G confers low activity to SLC19A1 Liu et al 2011, James et al 2010
TNFRSF11A
Codes for a member of the TNF-receptor superfamily. Like PLCG1 , is also 
involved in mast cell activtion. It also plays an important role in defense against 
pathogens, and blood–brain barrier function 
rs1805034 C>T
Allele T is associated with an increased risk of urticaria and Angioedema in 
patients who are treated with acetaminophen: patients with CC/CT genotypes are at 
higher risk compared to patients with the TT genotype.





Patients with the CC genotype may have an increased risk of liver failure due to 
unintentional acetaminophen overdose as compared to patients with the CG or GG 
genotype.
Court et al 2013
UGT2B15 Main UGT  responsible for bisphenol A glucuronidation rs1902023 A>C Allele C confers reduced metabolism to UGT2B15 Hanioka et al 2008 & 2011
VDR Vitamin D receptor rs731236 T>C
This polymorphism might alter VDR  mRNA levels through regulation of mRNA 
stability  and therefore affect its function 
 Cieslinska et al 2017, Fei et al 
2016
UGT1A gene cluster
Responsible for glucuronidation in phase  II metabolism which accounts for 
approximately 40% to 70% of xenobiotic elimination 
Allele C confers faster glucuronidation, which increases water-solubility of the 
chemicals
Mehboob et al 2017
PON1
Produces an enzyme that is involved in the inactivation by hydrolysis of 
organophosphate pesticides
Allele T & C result in reduced activity of paraoxonase enzymes, therefore less 
hydrolysis of organophosphates
D'Amelio et al 2005
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4.2 ELEAT RESULTS 
The population sample analyzed included 20 children with an age range  from 6 to 12 years old (mean 
age of 9,1), and a higher percentage of males (65%), in line with the male to female ratio in ASD. All 
children met criteria for ASD according to the DSM V. Furthermore, as seen in figure 3, some children (4) 
also presented a number of comorbidities such as speech or language disorder, developmental delay, 
intellectual disability, social communication disorder, epilepsy and attention deficit hyperactivity disorder.  
 
The probands’ biological mothers filled out the ELEAT. Parents’ age at probands birth ranged from 22 
to 38 years in mothers (mean age 29,7 years), and 24 to 40 years in fathers (mean age 32,7 years). As 
illustrated in figure 4, mothers’ education level ranged from 2º cycle to Post-Graduate, with the highest 
percentage (40%) having completed a bachelor's degree. Father’s education level ranged from 1º cycle to 
Bachelor's degree, with the highest percentage (60%) having completed High-School.  
 




















Figure 3 Comorbidities present in group of probands 
Figure 4 Parent's education level 
! 26!
Total household income (as seen in figure 5) fluctuated between less than 800 € per month to more than 
2699 € per month, with the highest percentage (30%) falling on 800€ to 1499€ per month category. Some 
mothers chose not to answer this question. 
Below the most relevant results for each module are highlighted. 
Results for module B (Breastfeeding and Child Diet), highlight that most infants where both breastfed 
(80%) and also given substitution milk (74%), with the majority of the mothers opting for cow derived 
substitution milk (71%). 70% of probands were fed with clear rigid plastic bottles. Of these, 4 out of 14 
contained BPA, while 9 out of 14 mothers did not know whether the plastic bottles contained BPA. 
Module M (Maternal Condition/ Medical Interventions) results show that only a moderate number of 
mothers had any kind of medical conditions or medical procedures and took medication during the period 
covered by the ELEAT. The highest percentages were: 36% of mothers were given oxytocin to speed labor 
process, 30% had dental cleanings or other dental procedures, 20% suffered from an influenza infection 
during pregnancy, 25% used prescription medication for pain, fever or inflammation during pregnancy and 
20% took female hormone medication. There was not a high use of pharmaceutical drugs reported by the 
mothers. Howerever, Ben-u-ron (20%) and Paracetamol (15%) were the most frequently used, while 
Nausefe, Atosiban, Primperan, Lamotrigine, Clavamox, Buscopan, Atarax, Valium, Antibiotics, 
Kompensan S, Gino-Canesten, Flagyl Ovule, Cerazette and Harmonet were each taken only once (5%). 
Regarding food consumption in Module D (Maternal Diet) we analyzed how often mothers ate cheese, 
eggs, fish and red meat. Results show that the most frequent consumption rate was that of 1-2 times per 
week for cheese (25%), eggs (30%), red meat (30%), and fish (35%), with the most consumed fish being 
horse mackerel (40%), gilthead bream (35%), hake (35%) and dried cod (30%). However, some mothers 
reported to never eating cheese (10%), eggs (10%) and fish (5%). Additionally, as seen in figure 6, a 
meaningful percentage of mothers (65%) consumed bottled water during and after pregnancy. 
 In terms of supplements (also illustrated in figure 6), results of module S (Supplements) highlight 
that mothers mainly took folic acid (80%), iron (70%), vitamins or supplements containing folic acid (65%), 
prenatal vitamins (45%), where 30% also contained iron, and finally, calcium supplements (32%). On the 
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other hand, there was no reported consumption of vitamin A or retinal, beta carotene, vitamin E, niacin, 
selenium, zinc, fish oil or omegae3 fatty acids, gingko biloba, St. John’s Wort, co-enzyme Q-10, or 
probiotics. 
In Module L (Lifestyle), 45% of mothers answered the question regarding sunlight exposure. From 
the hours reported by the mothers, it was calculated that an average of 6.2 hours per week were spent 
outside, and an average of 3.6 of these hours were during sunny periods of the day. Regarding caffeine, 
also shown in figure 6, a significant percentage of mothers (60%) reported consuming caffeinated coffee. 
Of these, 100% reported consuming it before pregnancy, more than a half  (66%) during pregnancy and 
(50%) while breastfeeding. Regarding smoking  and consumption of recreational drugs, none of the mothers 
consumed electronic cigarettes or any tobacco or nicotine products, alcohol, marijuana or any other 
recreational drugs. On the other hand, regarding second hand smoke, 30% reported that the biological father 
smoked cigarettes during the three months before conception, and 47% reported that they lived with 
someone who smoked cigarettes. However, of these, the majority (66%) reported that the cigarettes were 
always smoked outside their homes. In addition to this, no one living in the mothers’ homes smoked any 
other products anywhere inside the house. Hence the exposure to secondhand smoke was low, and there 
was little evidence for direct exposure to cigarette smoke. 
 Results of Module H (Home Environment) highlight that almost half of the mothers (45%) drank 
tap water, and the majority did not filter it in any way (66%). With respect to home-derived pollutants, 
fireplace was described to be the main heating source at home (35%), and the majority of the mothers used 
a gas stove (85%). However, 79% reported having a fume fan over the stove, and 87% of these indicated 
that they used it all/most of the time. Approximately one third of mothers (32%) answered affirmatively to 
having any mold or mildew on walls or other surfaces other than in the shower or bathtub. Concerning the 
house location relative to pollution sites, more than half of the mothers (53%) lived within ~400 meters of  
a busy road/highway, some lived within ~400 meters of an agricultural field or golf course (37%), but none 
lived within ~400 meters of a landfill. 
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 In module E (Environment), few mothers (40%) answered question relative to the potential 
exposure to PBDEs, namely regarding the number of stuffed furniture owned as this chemical is used in the 
polyurethane foam. It was calculated that, while pregnant, mothers owned an average of 5.6 pieces of 
furniture with cushions at home such as sofas and chairs with cushions. In addition to this, three months 
prior to becoming pregnant through the end of the first year after, over half of the mothers installed new 
carpets or rugs (60%). Lastly, 35% of the mothers reported painting/varnishing walls, ceilings, or furniture 
inside their homes.  
Concerning pesticide use, only a very low percentage of mothers (ranging from 5% to 16%) used 
any type of pesticides inside or outside their homes. 
In relation to the amount of times certain cosmetic products were used by the mothers, the most 
frequent rate of usage was 1 to 2 times per day, during pregnancy and during the child’s first year, for 
products such as: deodorant (65% and 63% respectively), lotion (60% and 58% respectively), liquid soap 
(50% and 42% respectively), and perfume (37% and 33% respectively). Nonetheless, hair gel, hair spray, 
and nail varnish/polish were not frequently used. 
 When examining occupational exposures in Module O (Occupation and Exposures), as seen in 
figure 7, results indicate that there was a very low rate of maternal exposure during pregnancy. The highest, 
but moderate, percentage of exposure was that of petrol exhaust, where 20% of mothers were exposed 
during pregnancy. No pattern was found in maternal or paternal occupation.  
 
The last module of the tool, Module I (Instrument Rating), consists of questions were the mothers 
rate the instrument. Concerning the length of the questionnaire, 45% of the mothers considered it a little 
too long, while 45% considered it much too long. In relation to questions regarding medical history, 
breastfeeding, diet, vitamins/supplements and lifestyle/substance use, between 85% and 53% of the mothers 
reported high certainty concerning their given answers. Only in questions regarding occupations/exposures 
and environment did the mothers express slightly lower confidence about their answers, with 42% and 47% 
















reporting high certainty, respectively. Notably, the latter questions are part of the last two module to be 
answered. When evaluating the questionnaire as a whole, 68% of the mothers found that the instructions to 
answer the tool were clear, and 53% felt sure about their answers. Additionally, 61% believed that the 
questions asked were important. Regarding the online questionnaire, the feedback was very positive. 
Mothers agreed that it was easy to understand the instructions (80%) and to!navigate through questions on 
the survey (93%).!
 For more detailed results, please refer to attachment S4, following each module. 
 
4.3 GENOTYPING RESULTS & EXPOSURE 
Out of the 20 participants who filled the ELEAT, we were able to obtain 16 biological samples: 9 
blood samples and 7 buccal swab samples. However, after quantifying each buccal swab sample using the 
NanoDrop Spectrophotometer, we chose to exclude 2 participants from this genotyping, as the DNA 
obtained was degraded (absorbance at 260nm and 280 nm – A260/280 ratio – was below the normal values 
1.80-2.00). Therefore, 14 DNA samples were used for the genotyping.  
Individuals were genotyped for particular genes according to environmental liability during early 
development. In this way, patients exposed to acetaminophen were screened for polymorphisms in genes 
UGT1A, PLCG1, and TNFRSF11A, and patients exposed to oxytocin were screened for the polymorphism 


















Subject 8 GC AA  -- yes
Subject 12 GC AA CT yes


























Table 7. Genotyping results for probands whose mothers took 
acetaminophen, and for those whose mothers took oxytocin.  Listed are the 
polymorphisms relevant for each drug. –: sequencing results had low 




All 14 individuals were genotyped for MTHFR, CYP2R1, VDR, AHR, UGT2B15, GSTM1, PON1, 
ACHE, ABCB1, CYP3A4, CYP2C19, and CYP2D6 (table 8) which are involved in the activity of various 
environmental factors such as folic acid, vitamin D, PAHs, BPA, organophosphate pesticides, heavy metals, 
and pharmaceutical drugs. Due to technical difficulties, we were unable to genotype polymorphisms in 
CYP1A1, SLC19A1, and UGT1A gene cluster. Electrophoresis gel results for the amplification of fragments 
containing the screened polymorphisms are shown in attachments S5 and S6, while the ones containing 
digestion patterns and GSTM1 genotyping are shown in attachments S7 and S8 respectively. An example 
of Sanger Sequencing results, for rs1854560 polymorphism of PON1 gene, is shown in attachment S9.  
We observed that some probands carried the minor allele of polymorphisms in the following genes: 
CYP2R1, VDR, AHR, GSTM1, UGT2B15, PON1, ACHE, ABCB1, CYP2C19 and CYP3A4. We also noticed 
that certain probands carried more than one genetic variant, in genes involved in the activity of different 
environmental factors. Taking into account that the frequency of the minor allele for rs1801133 of MTHFR 
is approximately 0.3397 in the European Non-Finnish population, it was surprising to note that it was not 
represented in our sample. Therefore, to ensure that our results were valid, we tested the HinfI enzyme used 
in digestion by selecting a DNA fragment from a known heterozygous subject for the polymorphism. 
Results showed that the enzyme was functional. 
Furthermore, we individually evaluated probands’ exposure by analyzing mothers’ answers to 
questions selected for each polymorphism (as seen in table 5). We established probands’ exposure to the 
environmental factor being analyzed according to: whether the mothers answered positively to questions 
regarding the specific environmental factor, or if they selected an answer option that potentially conveyed 
exposure to the specific environmental factor. On the other hand, in some cases we did not have enough 
information (e.g.: some mothers did not answer) to conclude that probands were exposed to the xenobiotic, 
but we also could not conclude that they were not exposed to it. Therefore, we chose the label “don’t know” 
instead of “no”. This was predominantly the case for variants involved in heavy metal and pesticide activity, 
as most of the questions regarding these exposures did not provide sufficient information to conclude 
exposure. For example, question 33 of Module E regarding exposure to heavy metals asked “was the blood 
of the child of interest tested for lead when he/she was young?”. Where half of mother answered “no” while 
the other half answered “don’t know”. Additionally, as seen in answers to question 11 in Module H, no 
mother reported having their drinking water tested for chemicals such as pesticides, lead, arsenic, nitrates, 
etc. Furthermore, although mothers did responded that they did not use pesticides directly, the information 






Table 8. Genotype results for all probands who were screened for polymorphisms in genes involved in the processing of different environmental factors, and their exposure to each one of these 
environmental factors. Minor alleles are represented in red. - -: sequencing results had low quality and therefore could not be read.  
MTHFR CYP2R1 VDR AHR GSTM1 UGT2B15
rs1801133 rs10741657 rs731236 rs4410790 GSTM1*0 rs1902023 
Subject 1 CC Yes AA TC Yes  -- Yes GSTM1 +/- Yes AA Don’t Know
Subject 2 CC Yes AA TC Yes TC Don’t Know GSTM1 +/+ Yes AC Don’t Know
Subject 3 CC Yes AA TC Yes TC Yes  -- Yes  -- Yes
Subject 4 CC Yes AA TT Yes TC Don’t Know GSTM1 +/+ Yes CC Don’t Know
Subject 5 CC Yes AA TT Yes TC Don’t Know GSTM1 +/- Yes AC Yes
Subject 6 CC Don’t Know AA TT Yes  -- Yes GSTM1 -/- Yes CC Don’t Know
Subject 7 CC Yes AG TT Yes TC Don’t Know GSTM1 +/+ Yes AC Yes
Subject 8 CC Yes AA TT Yes  -- Don’t Know GSTM1 +/- Yes AC Yes
Subject 9 CC Yes AG TC Yes CC Yes GSTM1 +/+ Yes CC Yes
Subject 10 CC Yes AG TT Yes CC Yes GSTM1 +/+ Yes AC Yes
Subject 11 CC Yes AG TC Yes TT Yes GSTM1 +/+ Yes AC Yes
Subject 12 CC Yes AG TT Yes TC Yes  -- Yes AC Yes
Subject 13 CC Yes AA TT Yes TC Yes GSTM1 +/- Yes AC Yes
Subject 14 CC Yes AA TT Yes CC Yes GSTM1 -/- Yes AC Yes
ACHE ABCB1 CYP3A4 CYP2C19
rs854560 rs662 rs2571598 rs1045642 rs2740574 CYP2C19*2 CYP2D6*4 CYP2D6*6
Subject 1 AA CC CT Don’t Know GG Yes TT GG  --  -- Don’t Know
Subject 2  -- TT  -- Yes GG Don’t Know  -- GG  --  -- Yes
Subject 3 AT  -- CC Don’t Know GG Yes TT GG  --  -- Yes
Subject 4 TT TT CC Yes GG Don’t Know TT GG  --  -- Yes
Subject 5 AA TC CC Don’t Know GG Don’t Know  --  --  --  -- Yes
Subject 6 AT  --  -- Don’t Know GG Don’t Know  --  -- CC AA Don’t Know
Subject 7 AT TT CC Don’t Know GG Don’t Know TT GG CC AA Don’t Know
Subject 8 AA TC TT Yes GG Don’t Know TT GG CC AA Yes
Subject 9 AT TC CC Yes GG Don’t Know TT GG CC AA Yes
Subject 10 AT TT CC Don’t Know GA Don’t Know TT GA CC AA Yes
Subject 11 AA TC CT Don’t Know GG Don’t Know TC GG  --  -- Yes
Subject 12 AA TC CT Don’t Know GG Don’t Know TT GG  --  -- Yes
Subject 13 TT TC CT Don’t Know GG Don’t Know TT GA CC AA Yes









Vitamin D Multiple xenobiotics Bisphenol A
Organophosphate pesticides Heavy metals
Exposure
Multiple pharmaceutical drugs & xenobiotics
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5. DISCUSSION 
There has been an accumulation of evidence pointing to the role played by environmental factors 
in ASD risk, such as the effects on neurodevelopment of endocrine disruptive chemicals like xenobiotics 
that affect metabolism and cross physiological barriers. As mentioned in the introductory part of this work, 
environmental risk may only account for a percentage of the total risk of ASD. A substantial contribution 
is given by genetic variants which interact at various levels with different environmental factors, giving rise 
to brain disturbing pathways and ASD phenotypic manifestation. This work set to explore and study gene-
environment interactions between several candidate genes and environmental factors. On doing so, we 
applied an environmental exposure questionnaire (ELEAT) and explored the presence of polymorphisms 
in a total of 18 candidate genes, in a sample of 14 individuals diagnosed with ASD. We aimed to detect 
variants relevant to organism’s response to disruptive exogenous factors. From the questionnaire’s answers, 
we observed that probands were indeed exposed to a number of environmental factors previously associated 
to ASD. Additionally, genotyping results indicate that offspring of this group of mothers carry variants in 
genes involved in the functioning of such factors. Most of these variants have not been previously associated 
with ASD, but have the potential to contribute to the disorder’s onset. 
 The gender ratio found in this study is in accordance with male prevalence bias, seeing as 65% of 
the probands were male, and is thus representative of the general ASD population. ELEAT results suggest 
that the majority of the infants were both breastfed as well as given cow derived substitution milk. 
Consumption of dairy products has been of particular concern due to the amount of chemical contaminants 
that may be introduced during milk production, dairy processing or packaging (Jahed Khanik, 2007). It has 
been suggested that most of these contaminants are veterinary drugs such antibiotics, steroid hormones, 
bovine growth hormone, parasiticide drugs, as well as pesticides and heavy metals (Jahed Khanik, 2007). 
Exposure to such chemicals may have detrimental effects on infants seeing as they do not have a fully 
developed immune system. Indeed breastfeeding mothers can pass such contaminants directly to infants 
through breast milk. Studies have found concerning levels of EDCs in mothers’ colostrum (Kalkbrenner et 
al., 2014; Yi et al., 2013), it is therefore safe to assume that infants that are breastfed and bottle fed at the 
same time may have an increased risk of being exposed.  
Furthermore, results suggest that a significant number of probands were fed with clear rigid plastic 
bottles, which have been recognized as a source of BPA. Four mothers confirmed that the feeding bottles 
did contained BPA while others didn’t know if this chemical was present in the bottles. It is important to 
note that the fact that some mothers did not know may be attributable to forgetfulness, or  mainly because 
the general population is not familiar with such terminology. Therefore, the number of children exposed to 
this EDC due to the use of plastic bottles may be greater than reported. In addition to this, a significant 
number of mothers reported consuming bottled water during and after pregnancy, which is also a BPA 
source. One of the polymorphisms screened in probands was rs1902023, whose allele C confers reduced 
metabolism activity to UGT2B15, a gene of high importance seeing as it is the predominant isoform of BPA 
glucuronidation in humans in phase II metabolism (Hanioka, Oka, Nagaoka, Ikushiro, & Narimatsu, 2011; 
Hanioka, Naito, & Narimatsu, 2008). Genotyping results revealed that 9 probands were heterozygous (AC), 
while 3 were homozygous for the minor allele (CC). Additionally, when analyzing exposure, results 
indicate that one of the homozygous probands was certainly exposed to BPA. Considering that this 
individual could not correctly metabolize it, the exposure to this chemical may have had negative 
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consequences during development as unmetabolized BPA would have accumulated and reached toxic 
levels.  
In regards to pesticides, there was a very low use of these chemicals by the mothers, indoors or 
outdoors. Pesticides are widely applied in agriculture and on livestock, and residues are able to infiltrate 
through the soil into surface water because of their water solubility (Lionetto, Caricato, Calisi, Giordano, 
& Schettino, 2013; Diamanti-Kandarakis et al., 2009). Therefore, we cannot exclude exposure completely 
during pregnancy and through the child’s first year of life. Recent studies detected pesticides in food, ground 
and drinking water, natural surface waters, and marine organisms (Lionetto et al., 2013). It is important to 
note that some mothers reported living near a golf or agriculture field. We genotyped probands for 
polymorphisms rs854560 and rs662 in the PON1 gene, which encodes the enzyme paraoxonase, involved 
in the inactivation of organophosphate pesticides in humans. The alternative alleles T and C respectively, 
have been linked to decreased paraoxonase activity against OP compounds, and associate with autism 
vulnerability (D’Amelio et al., 2005). We observed that, for rs854560, 5 probands were heterozygous (AT), 
while 2 were homozygous (TT) for the minor allele. Additionally, 6 probands were heterozygous (TC), 
while 2 were homozygous (CC) for the minor allele in rs662. Probands also carried polymorphisms in 
AChE, a key enzyme in the nervous system which hydrolyzes the neurotransmitter acetylcholine. This 
enzyme is essential for the normal functioning of the nervous system as it terminates synaptic transmission, 
preventing continuous nerve firings at nerve endings. In addition to this, it is the primary target of inhibition 
for organophosphorus pesticides, which bind to the enzyme and inactivate it (Lionetto et al., 2013). When 
screened for polymorphism rs2571598, 5 probands were heterozygous (CT) while 1 was homozygous (TT) 
for minor allele. Since this enzyme is targeted by pesticides, individuals who carry this polymorphism are 
even more sensitive to these chemicals, seeing as the alternative allele (T) confers reduced enzymatic 
activity and has been associated with reduced serum AChE levels (Reale et al., 2018). Interestingly, 
previous studies have already shown that individuals with ASD carry potentially pathogenic SNVs within 
the ACHE gene (Iossifov et al., 2015). It is important to highlight that individuals such as subject 13, which 
carrry the minor allele of all three polymorphisms (heterozygous for both rs662 and rs2571598 on PON1, 
and homozygous for minor allele in rs854560 of AChE), would probably have been highly susceptible to 
pesticides, and therefore exposure should have been avoided as much as possible. The exposure status of 
this individual is unknown since the mother answered negatively to questions regarding the use of 
pesticides. However, subject 13 may have been exposed by maternal consumption of contaminated foods 
or water during pregnancy and/or while breastfeeding. Thus, the ELEAT does not provide enough 
information, and other sources of information like dried blood spots collected at birth or deciduous teeth 
might be very useful to directly measure exposure.  
Regarding tobacco, although both direct and secondhand smoke are complex mixtures including 
nicotine, volatile organic compounds, and metals such as cadmium and lead, evidence does not support a 
strong causal link between direct maternal smoking during pregnancy and autism (Kalkbrenner et al., 
2014).Tobacco smoke also contains PAHs (Moorthy, Chu, & Carlin, 2015), one of the EDC compounds. 
Results, showed no direct exposure of our probands as none of the mothers smoked during pregnancy. 
However, there is evidence that exposure to secondhand smoke may disrupt neurodevelopment 
(Kalkbrenner et al., 2014). Some mothers reported that the biological father smoked cigarettes during the 
three months before conception, and others reported that they lived with someone who smoked cigarettes. 
It is important to note that, more than half reported that smoking took place outside the house, thus reducing 
contact with secondhand smoke. Residential proximity to freeway has also been associated with exposure 
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to traffic-related air pollutants such as heavy metals, diesel compounds (Tordjman et al., 2014; Lyall et al., 
2014) and PAHs (Moorthy et al., 2015), it is important to note that over half of the mothers reported living 
within ~400 meters from a busy road/highway. Genotyping results for rs4410790 in AHR revealed that 7 
probands were heterozygous, while 3 were homozygous for the minor allele (CC). AHR is a receptor that 
is activated by ligands such as PAHs, and in turn activates cytochrome P450 enzymes which metabolize 
this xenobiotic. PAHs are metabolized by these and other enzymes into reactive metabolites, which can 
elevate reactive oxygen species (ROS) and react with DNA (Moorthy et al., 2015). Rs4410790 has thus far 
only been associated with higher coffee consumption and lower plasma caffeine levels (Cornelis et al., 
2014). However, this may be the result of higher ARH activity, leading to a higher expression of cytochrome 
P450 enzymes responsible for the metabolization of caffeine. Following this rationale, higher ARH activity 
would also lead to higher expression of cytochrome P450 enzymes involved in the activation of PAHs. 
Therefore, individuals such as subject 9, 10 and 14 who are homozygous for the minor allele (CC), may be 
prone to the buildup of reactive PAH metabolites if phase II enzymes do not have the same capacity in 
clearance. Interestingly, subject 14, who was exposed to PAHs during development, is also homozygous 
for GSTM1*0 (deletion of GSTM1 in both alleles, will be further discussed), leading to an impaired phase 
II metabolism. This exposure may have led to detrimental effects in neurodevelopment.  
The ABCB1 gene encodes for P-glycoprotein, responsible for the protective functional properties 
of the blood-brain barrier (Møllgård, Dziegielewska, Holst, Habgood, & Saunders, 2017; Brambila-Tapia, 
2013). This protein is also abundant in the placenta, and was the first discovered to offer fetal protection 
against toxicity (Walker et al., 2017). When exposed to heavy metals, and reactive oxygen species, the 
expression of P-glycoprotein is upregulated (Miller, Bauer, & Hart, 2008). We examined whether probands 
were carriers of the causative alle in rs1045642, which has been associated with decreased P-glycoprotein 
expression in tissues studies, including placenta (Brambila-Tapia, 2013). Our results revealed that 1 
proband was heterozygous for this polymorphism (GA). Such genotype may have conferred a higher 
sensitivity to heavy metals, both during and after embryonic development. This individuals’ exposure is 
not clear seeing as we don’t have enough information from the mothers. 
The use of cosmetic products is widespread in the general population. However, studying the use 
of such products (e.g.: lotions and perfumes) in pregnant women is important as they can be a source of 
phthalate, which have also been recognized as EDCs (Lyall et al., 2014; Diamanti-Kandarakis et al., 2009; 
Kalkbrenner et al., 2014). Interviewed mothers did not completely exclude these products from daily routine 
during pregnancy, with the most frequently used cosmetic products being deodorant, lotion and liquid hand 
soap. We can therefore conclude that the children may have been exposed to some levels of phthalates. 
In terms of home environment, it was estimated that, while pregnant, mothers owned an average of 
5.6 pieces of furniture with cushions at home such as sofas and chairs with cushions, and over half reported 
installing new carpets or rugs three months prior to becoming pregnant through the end of the infant’s first 
year of life. Stuffed furniture is a potential source of PBDEs a compound used in polyurethane foam in 
furniture. These chemicals are released into the environment over time since they are not chemically bound 
to the materials in which they are used (Castorina et al., 2011; Kalkbrenner et al., 2014). The same principle 
applies to carpets, which are also a source of PBDE (Kalkbrenner et al., 2014). A study found that women 
having 3 or more pieces of stuffed furniture in their home had higher serum PBDE levels (Castorina et al., 
2011). Following this criteria, it can be presumed that interviewed mothers were living in an space 
contaminated with PBDEs, and therefore were exposed to these chemicals during pregnancy. This is 
worrying as this class of chemicals have been recognized as EDCs, which disrupt hormone signaling and 
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have been linked with increased risk of ASD onset. It has been speculated that PBDEs do this by disrupting 
the normal function of thyroid hormone, because they are structurally similar (Diamanti-Kandarakis et al., 
2009; Kalkbrenner et al., 2014). It has also been suggested that individuals with ASD show an abnormal 
immune activation when exposed to PBDEs when compared to controls (Koufaris & Sismani, 2015). An 
additional concerning factor, is that breast milk has been identified as a source of PBDEs exposure 
(Castorina et al., 2011; Kalkbrenner et al., 2014), as well as in cord and placental tissue (Castorina et al., 
2011). 
 We genotyped probands for polymorphisms in GSTM1 and UGT1A, both involved in phase II 
metabolism of multiple xenobiotics including phthalates and PBDEs. In normal physiological conditions, 
glutathione reductase enzyme activities are able to sustain a high total plasma glutathione level versus 
oxidized glutathione redox ratio (James et al., 2006). However, excessive oxidative stress can disturb this 
balance and result in oxidized glutathione being transported into the plasma, which has been observed in 
autistic children (James et al., 2006; Buyske et al., 2006). The variant examined in this pilot study is the 
deletion of GSTM1 (GSTM1*0), which results in reduced activity depending on the number of alleles 
deleted. Our results showed that 4 probands were heterozygous, while 2 were homozygous for GSTM1*0 
(GSTM1 was deleted in both alleles). This deletion has been thought to contribute to the onset of some cases 
of autism, due to the failure in detoxifying important compounds, including some that could be agents or 
products of oxidative stress, thus affecting brain development during gestation (Buyske et al., 2006). 
Therefore, probands who carry both deletions will be highly susceptible to a number of xenobiotics 
metabolized by glutathione S-transferase enzyme, such as phthalates and PBDEs. Results from the ELEAT 
show that both individuals were exposed to some of these chemicals. 
Genes from the UGT1A cluster also play a role in phase II metabolism: they glucuronidate and 
eliminate several exogenous compounds by turning lipophilic molecules into more water soluble molecules 
than can be easily excreted. Individuals homozygous for alleles C in both rs10929303 and rs8330 are 
characterized as fast glucuronidators, while individuals homozygous for alleles T and G, respectively, are 
considered slow glucuronidators (Mehboob et al., 2017). However, as genotyping was not successful, we 
were unable to screen for these polymorphisms in our group of probands.  
Overall, the incapacity to properly metabolize endocrine disruptive chemicals can lead to harmful 
consequences in neurodevelopment, seeing as these xenobiotics are known to disrupt hormone function, 
which are involved in developmental processes. It is important to note that the general population is exposed 
to some level of these chemicals daily. However, these are specially harmful for pregnant women as most 
of these chemicals are able to cross the physiological barriers. This is even more detrimental when fetuses 
carry polymorphisms such as the ones mentioned above which make them more susceptible and can lead 
to serious reactions when exposed to such EDCs, even in lower doses. This process could result in increased 
risk of ASD (Koufaris & Sismani, 2015) 
 ELEAT results demonstrate that there was a regular intake of iron and folic acid. Multiple studies 
have associated prenatal intake of folic acid with a decreased risk of ASD development (Lyall et al., 2014; 
Tordjman et al., 2014; Wang et al., 2017). Taking into account that studies have indicated that variants on 
genes involved in processing folate, such as MTHFR and SLC19A1, which are both involved in placental 
function (Carter, 2016), are common in children with ASD (James et al., 2010; Schmidt et al., 2012), we 
screened probands for SNPs in both genes. Results for polymorphism rs1801133 of MTHFR gene showed 
that probands were all homozygous for the wildtype allele (CC). No proband carried allele T, which has 
been related to reduced enzyme MTHFR activity (James et al., 2010; Liu et al., 2011; Schmidt et al., 2012). 
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This allele has been associated with increased folate requirement and elevated levels of homocysteine, with 
the latter being linked to negative health effects (James et al., 2010; Schmidt et al., 2012). Therefore, the 
study of this polymorphism is important seeing as mothers pregnant with children with SNPs such as this 
require higher amounts of folate for proper neurodevelopment (Schmidt et al., 2012). Due to technical 
difficulties, we were not able to successfully genotype probands for polymorphism rs1051266 of SLC19A1. 
Allele G of this SNP has been linked to reduced folate carrier protein, and therefore low plasma folate levels 
(James et al., 2010). Studying the accumulative effect of both these polymorphisms is very important 
considering that a 3-fold increase autism susceptibility has been associated with the combination of 
homozygous genotype (GG) for the alternative allele in rs1051266, and genotypes (CT/TT) in rs1801133 
(James et al., 2006). 
Low levels of vitamin D have been associated with risk of ASD and other developmental problems 
(Vinkhuyzen et al., 2017; Rebecca J. Schmidt et al., 2015; Cieślińska et al., 2017; Chen et al., 2016). 
Vitamin D can be obtained by exposure to sunlight, and also by the consumption of foods such as eggs, 
meat and fatty-fish (De-Regil, Palacios, Lombardo, & Pena-Rosas, 2016). ELEAT results indicate that 
mothers spent an average of 3.6 hours per week outside during sunny periods of the day. Although the 
World Health Organization supports sunlight exposure, they recognize that the recommended amount of 
time spent in the sun by pregnant women may vary due to certain factors: amount of skin exposed, time of 
day, latitude and season, sunscreen use, skin pigmentation, etc. 
(http://www.who.int/elena/titles/guidance_summaries/vitamind_supp_pregnancy/en/). Therefore, without 
a control group, we cannot reach any conclusions from this value. Additionally, most mothers consumed 
foods known to be a source of vitamin D. One of the most consumed types of fish was horse mackerel 
(40%), a type of fatty-fish that is rich in this nutrient. When investigating the presence of polymorphisms 
in CYP2R1 and VDR, which are both involved in processing vitamin D, we found the presence of the minor 
allele of both genes. Allele G in polymorphism rs10741657 of CYP2R1 has been associated with lower 
circulating levels of  25(OH)D and an increased risk of ASD (Rebecca J. Schmidt et al., 2015), while allele 
A in polymorphism rs731236 in VDR may be correlated with development of ASD symptoms (Cieślińska 
et al., 2017). It has been implied that individuals with VDR variants require higher levels of vitamin D 
considering that they might have different activation threshold compared to carriers of the wildtype allele 
(Cieślińska et al., 2017). We observed that 5 probands were heterozygous for rs10741657, while 5 were 
heterozygous for rs731236. Both polymorphisms affect function of these genes, and thus result in the 
incorrect activity of this vital vitamin, individuals such as subject 9 and 11 which are heterozygous for both 
polymorphisms, may be highly pre-disposed to vitamin D deficiency. Therefore, it can be presumed that, 
although mothers did expose fetuses to vitamin D, mothers of probands 9 and 11 would need higher doses 
of this vitamin in order to promote a healthy neurodevelopment. 
 Only a moderate number of mothers reported having any kind of medical conditions or using 
pharmaceutical drugs during the period covered by the ELEAT. A thorough investigation of this area is 
vital for ASD research, as developing fetuses may be exposed to pharmaceutical drugs that they cannot 
completely metabolize due to an undeveloped detoxification system (Shao, Stapleton, Lin, & Gallagher, 
2007) and are believed to have a heavier body burden compared to adults (Yi et al., 2013). A study has 
shown that, while fetal liver hematopoietic stem cells have an active phase II metabolism, due to high 
Glutathione S-Transferase expression, they lack a fully functional phase I metabolism. This is because 
CYP1A1, CYP2E1, CYP3A4, and CYP3A5 were expressed at low levels, while CYP1A2 and CYP3A7 were 
not detected (Shao et al., 2007). These results suggest that fetus metabolism is only partially functional. 
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This is important for drug metabolization as cytochrome p450 enzymes play a crucial role in the drug 
metabolism: families 1-3 are responsible to 70 to 80% of all phase I dependent drug metabolism (Wijnen 
et al., 2007). Therefore, low levels of cytochrome p450 expression is fetuses make them more susceptible 
to medication taken by mothers during pregnancy. 
From the medications taken by mothers who filled the ELEAT, Paracetamol, Ben-u-ron, Atosiban, 
Primperan, Lamotrigine, Clavamox, Atarax, Valium, Flagyl ovule and antibiotics all have active ingredients 
that are able to cross the placenta (Bremer et al., 2017; Valenzuela, Craig, Bernhardt, & Holland, 1995; 
Sørensen et al., 2000; Myllynen, Pienimäki, & Vähäkangas, 2003; Iqbal, Sobhan, & Ryals, 2002; Koss et 
al., 2012; Pacifici, 2006). Furthermore, Amoxicillin, Acetaminophen and Diazepam, which are some of the 
active ingredients taken by the mothers and able to cross the placenta, are also listed as being part of the 
top 200 most frequently consumed medications in Portugal. This fact is imperative as it indicates a high 
rate of consumption of chemicals with the potential to disrupt fetus development. 
Following the hypothesis that maternal drug metabolization is altered during pregnancy, thus 
increasing the expression of certain metabolism enzymes such as CYP2A6, CYP2B6, CYP3A4 and UGT1A4 
(Jeong, 2010), a higher dosage of pharmaceutical drugs metabolized by these enzymes may be necessary 
to reach the level required for treatment. However, it is plausible that the fetus will somewhat be exposed 
to a higher dosage of the medication before the over expressed maternal cytochrome p450 enzymes can 
lower its concentration. This implication should be considered as it may be of particular importance to fetus 
that carry genetic variants for low metabolizers in these enzymes, and therefore have a reduced capacity to 
metabolize such pharmaceutical drugs. 
A large portion of mothers reported consuming caffeinated coffee. A potential role played by 
caffeine in ASD onset has not been explored. CYP1A2 encodes for the main enzyme responsible for phase 
I metabolization of caffeine (Sulem et al., 2011). The fact that CYP1A2 expression decreases in mothers 
during pregnancy (Jeong, 2010), and is not detected in hematopoietic stem cells during fetal development 
(Shao et al., 2007) should be considered. Future studies should analyze polymorphisms in this gene in the 
mother. 
In our study, probands were genotyped for SNPs in CYP3A4, CYP2D6 and CYP2C19. CYP3A4 is 
a fundamental metabolization enzyme in human adults due to the broad substrate specificity which includes, 
not only a large number of pharmaceutical drugs, but also many xenobiotics (Klein & Zanger, 2013). 
Although the effect of SNP rs2740574 is still under investigation, it has been suggested that the C allele in 
this polymorphism increases CYP3A4 expression due to higher transcriptional activity (Basheer & Kerem, 
2015; Klein & Zanger, 2013). Our results show that only one proband was a carrier of the C allele. The 
proband is heterozygous, and therefore may be unable to benefit from the higher enzymatic activity 
conferred by this allele. This could lead to an increased clearance of substrates metabolized by CYP3A4. In 
relation to CYP2D6, given the low frequency of both CYP2D6*4 and CYP2D6*6  (0.1959 and 0.0146 in 
European Non-Finnish, 0.08025 and 0.002039 in African population), none of the probands were carriers 
of the minor alleles, which are considered null alleles as they do not encode for functional protein products. 
However, these SNPs are of high importance given that they can result in the inability to eliminate substrates 
dependent of CYP2D6 metabolic activity, thus increasing the probability of adverse drug reactions (Zanger, 
Raimundo, & Eichelbaum, 2004). Similarly, CYP2C19*2 also results in loss of function caused by the 
creation of an aberrant splice site, which produces a truncated, nonfunctional protein. The genotype of 
intermediate metabolizers (IM) consists in the combination of one wildtype allele and one variant allele, 
such as CYP2C19*2, resulting in decreased CYP2C19 activity (e.g.:*1/*2), while a poor metabolizer (PM) 
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genotype consists of two loss-of-function alleles resulting in significantly reduced or absent CYP2C19 
activity (e.g.*2/*2) (Scott et al., 2012). We observed that two probands were heterozygous for this 
polymorphism (*1/*2), thus suggesting that they are intermediate metabolizers (IM). Both individuals were 
exposed to pharmaceutical drugs. It is important to add that, as there are more loss-of-function 
polymorphisms in this gene, we cannot conclude with certainty the metabolizer status of these subjects: for 
example, if one of the CYP2C19*2 carriers has yet another allele that confers low enzymatic activity, he 
may be a poor metabolizer. However, if these individuals are truly IMs, then they could still efficiently 
metabolize the pharmaceutical drugs if this was not present in high concentrations.  
Moreover, we analyzed relevant polymorphisms in probands whose mothers took a specific drug 
during the period covered by the ELEAT. Because we did not receive biological samples from all probands, 
we were only able to test for polymorphisms related to the activity of acetaminophen and oxytocin. Results 
from probands who were tested for SNPs affecting the effect of acetaminophen, the most frequently taken 
medication among mothers, indicated that: out of the three probands tested, one was heterozygous in 
rs1042640 of the UGT1A gene, another was heterozygous in rs1805034 of TNFRSF11A, and finally, one 
was heterozygous of both polymorphisms. However, none carried the alternative allele in rs2228246 of 
gene PLCG1. Homozygous genotype for the minor allele (C) of the UGT1A SNP has been associated to an 
increased risk of liver failure due to unintentional acetaminophen overdose (Court et al., 2013). Meanwhile, 
due to their involvement in the activation of mast cells, both TNFRSF11A and PLCG1 genes were studied 
in relation to allergic reactions leading to angioedema and urticaria in patients treated with a number of 
medications including acetaminophen. In this study, only rs1805034 of TNFRSF11A was found in higher 
frequency among the group that suffered from these allergic reactions compared to control groups, while 
the frequency of rs2228246 in PLCG1 was lower in the case group compared to control (Ayusoa et al., 
2015). These results are comparable to ours since probands carried the alternative allele of rs1805034 (T) 
but none carried allele G in rs2228246. None of these SNPs have been directly linked to ASD. However, 
they are still of some importance as the pathways in which they affect drug activity may indirectly increase 
ASD risk: the SNP in UGTA affects the liver, which is a vital organ involved in the metabolization of 
various xenobiotics in the body, and SNPs in TNFRSF11A and PLCG1 are both involved in the abnormal 
activation of mast cells, which seem to play a key role in inflammation and in the disruption of the blood 
brain barrier (Polyzoidis, Koletsa, Panagiotidou, Ashkan, & Theoharides, 2015), and thus could be related 
to ASD risk. Regarding OXTR, rs2268498 has been associated with autistic traits in various cultural groups 
(Montag 2017). Genotyping results revealed that 1 proband was heterozygous (TC), while 2 were 
homozygous for minor allele (CC). While T allele has been associated with lower OXTR expression, which 
is thought to reflect higher oxytocin sensitivity, the C allele has been associated with higher ASD scores in 
Autism -Spectrum Quotient test (Montag 2017). Following this notion, it can be presumed that allele C 
confers higher expression, thus resulting in reduced oxytocin sensitivity, which plays an important role on 
social cognition. Future studies should screen for this polymorphism in all case patients. 
Considering these results, we can conclude that probands were carriers of polymorphisms that may 
influence the correct processing of certain environmental factors studied by the ELEAT, thus making them 
more susceptible than the general population. For the ones that were exposed to such xenobiotics during 
critical developmental periods, this could have played a role in ASD onset. It is important to note that sole 
exposure to such environmental factors is not sufficient to set in motion the mechanisms that lead to 
neurodevelopmental problems. It is however the combination of exposure and genetic susceptibility to such 
factors that may lead to heavier consequences.  
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This pilot study is an important step for future studies that intend to use the ELEAT to identify 
environmental risk factors for ASD. The addition of genetic factors has proven to be complementary to the 
questionnaire and therefore allow for more meaningful results. This combination helps reach more solid 
conclusions considering the fact that it provides a biological explanation to why the potential factors found 
by the ELEAT may be associated with ASD risk. As everyone is generally exposed to some levels of these 
chemicals, genetic factors play a crucial role and cannot be ruled out. Therefore, we believe that the 
proband’s genotype is of crucial importance: knowing if the infant is particularly sensitive to some of the 
chemicals they were exposed to is essential when considering cause and effect of environmental factors. 
Consequently, it is important for future studies to not only interpret ELEAT group results, but to also study 
each case individually and investigate the exposure level of each child to the xenobiotics they may be unable 
to efficiently metabolize. This information can only be obtained by genotyping each proband, and searching 
for rare and common variants that are involved in the processing of the xenobiotics studied by this 
questionnaire. 
Nowadays, researchers suggest that ASD is caused by an accumulation of genetic and 
environmental factors that push the individual to reach a certain threshold, which results in the onset of the 
pathology (Eapen, 2011; Chaste & Leboyer, 2012). Therefore, ELEAT’s ability to measure multiple factors 
simultaneously gives it an advantage over studies that measure single exposures. It is believed that common 
variants, like the polymorphisms analyzed in this pilot study, are distributed continually in the general 
population but can result in a broad range of ASD phenotypes when they accumulate to reach a certain 
threshold (Eapen, 2011). Further investigation of the contribution of environmental factors through additive 
or multiplicative effect has been called for (Chaste & Leboyer, 2012), and, as demonstrated in this pilot 
study, the ELEAT has the potential to explore this area. It is important to note that the tool aims simply to 
gather information about environmental exposure and is not to be used as a diagnosis instrument. 
Taking into account that this is a standardized tool, the ELEAT has the potential of being applied 
in different countries and gather a large amount of data that could be analyzed together and lead to 
meaningful findings. It has been noted that the translation of instruments such as the ELEAT may present 
some cross-cultural problems, thus compromising its validity. However, in this pilot study, these are 
minimized by the fact that there is not a large discrepancy between the lifestyle and habits of British vs 
Portuguese mothers. Both have similar access to hospitals, consultations, dietary supplements, baby 
formula, usage of baby-bottles, etc., which are some of the areas in which the questionnaire focuses on. In 
terms of comprehensiveness, the Portuguese language is very uniform in the Central Region, thus 
diminishing the chances of misinterpretation of the questions between the mothers due to different regional 
terms. In order to ensure that the mothers understand the questions asked, it is important to offer assistance 
to fill out the questionnaire, thus erasing any doubts they may have.  
The main limitation of this tool is its length: as seen by the results in Module I (Instrument 
Evaluation), the tool is considered to be extensive. This was one of the principal reasons for the limited 
sample size of this study. Seeing as the questionnaire is 80 pages long and demands at least 1hour to be 
filled, many mothers did not return to complete it, despite our best efforts. A revision of the questionnaire 
is recommended, so that a shorter and more direct version could be created. In addition to this, the questions 
have proven themselves complex to extract quantitative information from, which is necessary for the 
creation of a score. Therefore, the creation of a rational to transform qualitative into quantitative results is 
a crucial step to improve the statistical power of ELEAT conclusions. On the other hand, results also showed 
that mothers felt that the instructions to answer the tool were clear, and the majority felt sure about their 
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answers. In addition to this, they also appreciated the possibility of filling it online, and gave very positive 
feedback regarding this process. Feedback from this module is essential, considering that this tool is still 
being molded to improve its capacity to assemble accurate data from diverse populations. Due to the use of 
scientific terms in the questionnaire, it is especially important to offer assistance to participants with lower 
education in order to guarantee accurate data collection. By tackling this and the length of the questionnaire, 
it is plausible that the selection of “don’t know” will decrease. Seeing as indirect measures may not be as 
accurate as direct ones, the ability of the ELEAT to measure exposure to exogenous factors could be 
validated by the analysis of neonatal archived dried blood spots: if xenobiotics in blood test match the 
exposures recorded in the questionnaire, it would confirm the validity of this tool. The main limitation of 
this pilot study is the sample size. Having only 20 participants, and 14 valid biological samples made it 
impossible to draw significant statistical results. However, the purpose of this pilot study was to explore 
the type of results that can be obtained from the ELEAT questionnaire, how these could be related to genetic 
variants, and thus applied to study gene-environment interactions. Despite the small sample, we were able 
to reach our goals and demonstrate that this tool, when combined with biological approach, has the potential 
to yield significant results that may bring about important breakthroughs in the area of gene-environment 
interaction studies. Now that it has been shown that ELEAT can be applied, we are expanding its application 
to other regions of Portugal, such as Lisbon. 
  
! 41!
6. CONCLUSION & FUTURE STUDIES  
In conclusion, the addition of a biological approach has proven to be complementary to the ELEAT, 
and lead to more comprehensive results. This pilot study is an important step for future studies that intend 
to use the this tool to measure environmental factors related to ASD risk. Follow-up studies should include 
larger population datasets, depending on the effect size of the interaction between genetic susceptibility and 
environmental factors. An equal number of typically-developing controls should be included. With a large 
sample, researchers could also study rare genetic variants, which have been shown to be important in ASD, 
in addition to common ones. Moreover, both biological parents should also be genotyped to provide a more 
clear understanding of proband’s genotype (to know if a given variant is de novo or inherited), and the 
chemicals they were exposed to depending on the mother’s metabolism. Despite the limitations of this pilot 
study, the application of the ELEAT, as well as the genotyping methodology, have been successfully tested. 
This should be considered one of the strengths of this work. Indeed, once a pipeline has been tested and 
approved in a smaller pilot sample, all succeeding work should be faster and more consistent. The long-
term goal is to use this knowledge to contribute to the development of preventive strategies for autism by 
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UGT1A4 rs2011425 Level 2B other T > G 0.08772 0.1003
HNF4A rs2071197 Level 3 efficacy/pk G > A 0.1080 0.02304
SLC22A1 rs628031 Level 3 dosage/efficacy/pk A > G 0.5852 0.7284
SCN2A rs2304016 Level 3 efficacy A > G 0.001916 0.0002946
ABCG2 rs2231142 Level 3 efficacy/pk G > T 0.1036 0.02738
SCN1A rs2298771 Level 3 efficacy C > T 0.6791 0.8287
UGT1A rs1042640 Level 3 toxicity G > C 0.7937 0.8008
PLCG1 rs2228246 Level 3 toxicity A > G 0.1713 0.1011
TNFRSF11A rs1805034 Level 3 toxicity C > T 0.5097 0.6446








1. Thoroughly homogenize blood collected in EDTA and decant into the polypropylene tube; 
2. Add to each tube the volume of TKMX-100 equivalent to the initial blood volume (see attached table), 
and shake vigorously. 
3. Add IGEPAL (25µL per mL of blood, see attached table) and shake by inversion until you reach 
complete solubilization; 
4. Centrifuge at 974 rcf (2200 rpm for centrifuge 1011997) for 10minutes at 18 °C, with acceleration 9 
and brake 7; 
5. Discard the supernatant by decantation into the waste vial; 
6. Add TKM1 to the pellet (1 mL per mL of blood, see attached table) and shake by inversion; 
7. Centrifuge at 515 rcf (1600 rpm for centrifuge 1011997) for 10minutes at 18 ° C, with acceleration 9 
and brake 7. Discard the supernatant. 
8. Repeat steps 6, 7 and 8 once (if necessary repeat once more); 
9. Resuspend the pellet with TKM2 (160µL per mL of blood, see table attached). Shake vigorously. 
10. Add 10% SDS (10µL per mL of blood, see attached table) and shake vigorously; 
11. Incubate in the thermostated bath at 55 ° C for 10 '; 
12. After incubation, transfer the contents of the polypropylene tube with a Pasteur pipette to a 2.0 ml 
polypropylene microtube; 
13. Add 5M saturated NaCl (60µL per ml of blood, see attached table) and shake well by inversion; 
14. Centrifuge for 20minutes at 16,100 rcf (13,200 rpm for centrifuge 1015704) at 18 ° C; 
15. Transfer the supernatant with a Pasteur pipette into a 15mL polypropylene tube, without dragging the 
proteins; 
16. Add absolute ethanol (2.3 mL per 5 mL of blood, see attached table) and homogenize slowly by 
inversion until the DNA pellet is visible; 
17. Remove the DNA with a plastic inoculation loop and wash with 70% Ethanol. Let the loop with the 
DNA rest vertically for approximately 5minutes ; 
18. Place the loop in a 1.5mL conical bottom microtube with 150µL of TE and semi-close the tube cap so 
that the plastic inoculation loop is broken and remains inside. 
 
Attachment I - Solution volume / blood sample volume 
 
Blood  TKMx100 IGEPAL TKM1 TKM2 SDS NaCl EtOH TE 
2,5 mL 2,5mL 62,5µL 2,5mL 400µL 25µL 150µL 1150µL 150µL 
3 mL 3mL 75µL 3mL 480µL 30µL 180µL 1380µL 150µL 
4mL 4mL 100µL 4mL 640µL 40µL 240µL 1840µL 200µL 





1. Transfer the solution to a 2ml round bottom tube 
2. Centrifuge at 3000rpm for 10min at room temp. 
3. Remove 400ul of the supernatant into a 2ml round bottom tube 
4. Add 10ul of proteinase K 
5. Mix in vortex 
6. Incubate for 20 min at 55 ° C 
7. Add 160ul TKM2 + 10ul SDS 10% 
8. Incubate for 10 min at 55 ° C 
9. Add 140 ul of 5M NaCl and homogenize by inversion 
10. Centrifuge at 13200rpm for 20 min 
11. Remove supernatant to a 2ml round bottom tube 
12. Add 500ul of absolute ethanol and shake gently until you see the DNA fibrils 
13. Centrifuge at 13200rpm for 1min 
14. Remove the supernatant 
15. Add 500ul of ethanol 70% 
16. Centrifuge at 13200rpm for 1min 
17. Remove the supernatant 
18. Leave the tubes open inside the chamber for at least 20 min to dry the DNA pellet. 
19. Resuspend the DNA in TE (80ul) 
20. Quantify and verify DNA integrity. 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A.!!Agriculture!/!Farming! 0%' 0% 0% 0%'
B.''Creative!artist!or!from!show!
business! 0% 0% 0% 5%'
C.'' Author/!journalist/!linguist! 0% 0% 0% 0% 
D.'' Hairdresser/!beautician! 0% 0% 0% 0% 
E.'' Sciences!(laboratory!
technician/researcher)! 0% 0% 0% 0% 
F.' Merchant/!salesman/!




10%' 10%' 10%' 0%'
H.'' Lawyer,!jurist,!judge! 0% 0% 0% 0% 
I.!!! Computer!technician!
(computer!engineer,!etc.)! 5%' 5%' 5%' 5%'
J.''!Repair!Services!/!Mechanic!/!
Plumber/!painter/!electrician! 0% 0% 0% 10%'
K.!!Military! 0% 0% 0% 0% 
L.''Driver/!taxi!driver/!train!driver! 0% 0% 0% 0% 
M.!!Factory!worker! 5%' 5%' 5%' 10%'
N.''Fisherman!/!aquaculture! 0% 0% 0% 0% 




5%' 5%' 5%' 5%'
Q.! Public!security!professional!!!




0% 0% 0% 15%'
S.''Construction!Worker' 5%' 5%' 5%' 5%'
T.'!Work!in!an!office!
environment' 15%' 15%' 15%' 5%'
U.'!Other!
___________________' 25%' 25%' 20%' 15%'
V.'!Not!Employed' 10%' 10%' 0%' 0%'
W.'Unknown' 0% 0% 0% 0% 


































































































































































































































































































































Attachment S6: 1.8% electrophoresis gel containing amplification fragments for the polymorphisms analyzed 
by Sanger Sequencing for medications taken by the mothers. Lanes 1-5 (312bp) are for the 5 subjects analyzed 
for rs2268498 polymorphism of OXTR, lanes 6-8 (332bp) are for the 3 subjects analyzed for rs1805034 polymorphism 
of TNFRSF11A, lanes 9-11 (306bp) are for rs2228246 polymorphism of PLCG1; lanes 12-14 (487bp) are for 























Attachment S7: 1.8% electrophoresis gel containing amplification fragments for the polymorphisms analyzed by Sanger 
Sequencing in all 14 subjects. Two examples of the obtained fragments are shown for each polymorphism. Lanes 1a and 1b 
(389bp) – rs4410790 polymorphism for AHR; lanes 2a and 2b (337bp) – rs662 polymorphism for PON1; lanes 3a and 3b (332bp) 
– rs854560 polymorphism for PON1; lanes 4a and 4b (316bp) – rs2571598 polymorphism for ACHE; lanes 5a and 5b – rs2749574 
polymorphism for CYP3A4 (329bp); lanes 6a and 6b (443bp) – CYP2D6*4 and CYP2D6*6 (both are present in a fragment 
amplified through the same pair of primers) for CYP2D6; lanes 7a and 7b (301bp) – CYP2C19*2 for CYP2C19; lanes 8a and 8b 
(487bp) – two polymorphisms for UGT1A (we were unable to sequence); lanes 9a and 9b (267bp) – rs1902023 polymorphism for 
UGT2B15 gene. L stands for 100bp DNA Ladder (Bioron). 
 
  
  L        1         2         3        4        5        6         7         8             9       10      11        12      13       14            
                            OXTR                                    TNFRSF11A                       PLCG1                        UGT1A 
 L    1a   1b       2a   2b       3a  3b      4a   4b      5a   5b        6a  6b     7a   7b       8a    8b      9a   9b 






Attachment S8: 3% electrophoresis gel with examples of genotype patterns for each polymorphism assessed through RFLP.  
Lanes 1, 2 and 3 are for rs1045642 polymorphism of ABCB1 (lane 1 corresponds to heterozygous GA subject 10 that displays three 
bands of 206bp, 130bp and 76bp and lanes 2 and 3 correspond to homozygous GG subjects 4 and 8 which display two bands of 
130bp and 76bp). Lanes 4 to 7 are for rs10741657 polymorphism of CYP2R1 (lanes 4 and 5 correspond to heterozygous AG 
subjects 7 and 9, displaying three bands of 300bp, 248bp and 52bp and lanes 6 and 7 correspond to homozygous AA subjects that 
display two bands of 248 and 52bp). Lanes 8 to 11 are for rs731236 polymorphism of VDR (lanes 8 and 9 correspond to 
heterozygous TC subjects 2 and 9, which display three bands of 630, 425 and 205bp, while lanes 10 and 11 are for homozygous 
TT subjects that display two bands of 425 and 205bp). Lanes 12, 13 and 14 are for rs1801133 polymorphism of MTHFR, of which 
all 14 subjects where homozygous CC (shown are bands for subjects 2, 9 and 10). L stands for 100bp DNA Ladder (Bioron). 
!
  
   ABCB1 
1      2      3 
        CYP2R1 
 4       5        6       7 
           VDR 
   8        9        10       11 
           MTHFR 







Attachment S9: 1.8% electrophoresis gel with genotype pattern of GSTM1 for the 14 assessed subjects. As stated in methods 
section, two pairs of primers were used for each subject resulting in two lanes: if there is deletion of GSTM1 a band of 433bp 
appears in the first lane, while the presence of GSTM1 corresponds to a 379bp in the second lane. Heterozygous subjects  
(GSTM1+/-) will have both bands, while homozygous GSTM1-/- or GSTM1+/+ will have a band only in the first or second lane, 
respectively. Subjects 2, 4, 7, 9, 10 and 11 are homozygous for the presence of the gene (GSTM1 +/+). Subjects 6 and 14 are 
homozygous for the deletion of the gene (GSTM1 -/-). Subjects 1, 5, 8 and 13 are heterozygous (GSTM1 +/-). No pattern was 




 L         Subj. 1        Subj. 2          Subj. 3         Subj. 4       Subj. 5         Subj. 6        Subj. 7 





Attachment S10: Partial sequencing electropherogam obtained for the genotyping of PON1 regarding rs854560 
polymorphism.  A – Heterozygous (AT) subject 9; B – Homozygous AA subject 11; C – Homozygous TT subject 4!
!
!
